Published in final edited form as:

J Med Chem. 2019 June 13; 62(11): 5470–5500. doi:10.1021/acs.jmedchem.9b00352.

Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis

Christopher L. Cioffi^{*,†}, Boglarka Racz[‡], Andras Varadi[‡], Emily E. Freeman[§], Michael P. Conlon[§], Ping Chen[§], Lei Zhu^{||}, Douglas B. Kitchen^{||}, Keith D. Barnes[§], William H. Martin[⊥], Paul G. Pearson[#], Graham Johnson[∇], William S. Blaner[○], Konstantin Petrukhin^{*,‡}

[†]Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States

[‡]Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032, United States

[§]Department of Medicinal Chemistry AMRI, East Campus, 3 University Place, Rensselaer, New York 12144, United States

^{||}Computer Assisted Drug Discovery, AMRI, East Campus, 3 University Place, Rensselaer, New York 12144, United States

[⊥]WHM Consulting LLC, 111 Sterling City Road, Lyme, Connecticut 06371, United States

[#]Pearson Pharma Partners, 31194 La Baya Drive, Westlake Village, California 91361, United States

[∇]NuPharmAdvise LLC, 3 Lakeside Drive, Sanbornton, New Hampshire 03269, United States

[○]Department of Medicine, Columbia University Medical Center, New York, New York 10032, United States

Abstract

Retinol-binding protein 4 (RBP4) serves as a transporter for all-*trans*-retinol (**1**) in the blood, and it has been proposed to act as an adipokine. Elevated plasma levels of the protein have been linked

^{*}**Corresponding Authors** christopher.cioffi@acphs.edu. Phone: 518-694-7224 (C.L.C.), kep4@cumc.columbia.edu. Phone: 212-305-9040 (K.P.).

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.jmed-chem.9b00352](https://doi.org/10.1021/acs.jmed-chem.9b00352). RBP4 in vitro assay protocols, mouse PK study protocols, rat PK study protocol, serum RBP4 collection and measurements, protocols for the adipocyte-specific hRBP4 transgenic mouse experiments, general chemistry information, ¹H NMR, MS, and HPLC data for compounds **48** and **59**; molecular formula strings for biologically tested compounds (PDF)

Accession Codes

Docking was performed only with PDB entry 3FMZ (RBP4 cocrystallized with 3) (PDB). Authors will release the atomic coordinates and experimental data upon article publication.

The authors declare the following competing financial interest(s): C.L.C., E.E.F., M.P.C., L.Z., P.C., G.J., and K.P. are inventors on the patent applications for compounds disclosed in this paper that are assigned to The Trustees of Columbia University in the City of New York.

to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD). Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice. We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in *Abca4*^{-/-} knockout mice with concomitant normalization of complement system protein expression and reduction of bisretinoid formation within the retinal pigment epithelium. We describe herein the discovery of novel RBP4 antagonists **48** and **59**, which reduce serum RBP4 levels by >80% in mice upon acute oral dosing. Furthermore, **59** demonstrated efficacy in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may also have therapeutic utility for the treatment of NAFLD.

Graphical Abstract

INTRODUCTION

Retinol-binding protein 4 (RBP4) is a serum protein belonging to the lipocalin family that transports the essential vitamin all-*trans*-retinol (vitamin A, **1**) (Figure 1) from the hepatic stores to peripheral tissues.¹ RBP4-mediated transport of **1** from the liver to target tissues requires formation of a tertiary complex between holo-RBP4 (RBP4 bound to **1**) and transthyretin (TTR)² as circulating apo-RBP4 (RBP4 not bound to **1**) associates poorly with TTR and due to its low molecular weight (21 kDa), it is rapidly cleared via glomerular filtration.³ Inhibition of holo-RBP4 formation by displacing **1** from the ligand-binding pocket of RBP4 by selective antagonists prevents RBP4–TTR complexation from occurring, which in turn leads to a reduction in circulating levels of RBP4 and **1**. Cellular uptake of **1** is facilitated by Stimulated By Retinoic Acid 6 protein (STRA6), which functions as a high-affinity RBP4 membrane receptor and a retinol channel in many vitamin A-dependent tissues and blood–organ barriers.⁴ Until recently, transport of **1** was the only function attributed to RBP4. Consistent with its major role as a carrier of hepatic **1**, 60–80% of circulating RBP4 derives from the liver where it is secreted bound to **1**⁵ with extra-hepatic secretion, mainly from adipocytes, accounting for approximately 20–40% of circulating levels of the protein.^{6–8} Recently, emerging epidemiologic evidence suggested that modestly enhanced circulating levels of RBP4 might have important metabolic effects. Numerous, but not all, epidemiological studies established an association of elevated serum RBP4 levels with obesity,^{8,9} insulin resistance,^{8–11} cardiovascular disease,^{12,13} pro-atherogenic conditions,⁸ hepatic steatosis,⁹ and type 2 diabetes.^{8,11} It has been theorized that RBP4 may act as an adipokine (a cytokine produced by adipocytes) involved in the mediation of insulin

sensitivity and the regulation of energy metabolism.² Consistent with this hypothesis, it was reported that RBP4 secreted from cultured adipocytes may activate cytokine production from cocultured macrophages through TLR4 and JNK pathway activation that does not involve the RBP4 receptor STRA6.^{13,14} It was suggested that retinol binding may not be required for RBP4 to act as a pro-inflammatory metabolic effector, given that apo-RBP4 was shown to induce an inflammatory response in endothelial cells by stimulating the expression of pro-inflammatory signaling molecules in a retinol- and STRA6-independent fashion.¹⁵ Conversely, it has been reported that RBP4 signaling depends on retinol binding and involves the STRA6 receptor.^{16,17} Despite the progress made in the characterization of RBP4 as a putative adipokine, it is not fully understood how modestly elevated serum RBP4 levels in humans may mechanistically contribute to the pathogenesis of a variety of metabolic disorders. Three mouse models mimicking the increase in circulating levels of serum RBP4 were used to probe the role of RBP4 in mediating adverse metabolic consequences. Transgenic mice ectopically expressing human RBP4 in muscle from a muscle-specific promoter have approximately 3-fold higher circulating levels of serum RBP4.¹⁸ These mice were reported to develop high-fat diet (HFD)-induced insulin resistance,⁹ although two subsequent studies could not replicate this finding.^{19,20} Adeno-associated virus-driven overexpression of murine RBP4 in the mouse liver yielded a 2–3-fold increase in levels of serum RBP4.²¹ However, no effect on glucose and energy homeostasis was detected in response to this significant increase in liver-secreted circulating RBP4.²¹ In a remarkable contrast to the two previous models, low-level transgenic expression of human RBP4 in the mouse adipose tissue led to a strong metabolic phenotype, which comprised hepatic steatosis, dyslipidemia, and reduced glucose tolerance.²² Given that hepatic steatosis observed in this model resulted from increased hepatic uptake of adipose-derived circulating nonesterified fatty acids,²² it may be suggested that adipose-secreted RBP4 facilitates trafficking of the adipose-derived fatty acids to the liver through a yet to be defined mechanism. Interestingly, earlier crystal structures of heterologously expressed RBP4 display fortuitous fatty acid ligands from the expression host in the ligand binding pocket of RBP4.^{23,24} Furthermore, recent X-ray crystallographic and mass spectrometry (MS) findings reported by Monaco and co-workers confirmed that in addition to binding retinoids, RBP4 is also capable of binding fatty acids,²⁵ which may potentially relate to the RBP4 role as a facilitator of fatty acid trafficking. We previously described the discovery of new classes of non-retinoid RBP4 antagonists^{26,27} that we studied in animal models of retinal disease.²⁸ In light of the aforementioned studies, it seems reasonable to suggest that synthetic RBP4 ligands may also serve as important pharmacological tools in assessing the role of RBP4 in the pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Here, we report the characterization of a new class of nonretinoid RBP4 antagonists and their assessment in the mouse transgenic model of hepatic steatosis.

Protein Data Bank (PDB) high-resolution X-ray crystal structures providing binding poses of various ligands bound to RBP4 were studied during our structure-based drug design efforts to discover novel nonretinoid RBP4 antagonists. These structural data include RBP4 cocrystallized with **1** (PDB 1RBP), **1** bound to the RBP4–TTR tertiary complex (pDB 3BSz), RBP4 cocrystallized with the retinoid RBP4 antagonist fenretinide (**2**) (PDB 1FEL),

and RBP4 cocrystallized with the nonretinoid RBP4 antagonist A1120 (**3**) (PDB 3FMZ).^{26,27} Initial rational design efforts derived from the aforementioned structural data provided optimized bicyclic antagonists **4** and BPN-14136 (**5**). Importantly, **5** presented exceptional in vitro RBP4 binding and functional antagonist activity, desirable absorption, distribution, metabolism, and excretion (ADME) characteristics, and a favorable pharmacokinetic (PK) profile. In addition, **5** dramatically reduced circulating RBP4 levels in vivo with good pharmacokinetic/pharmacodynamic (PK/PD) correlation in rodents. Furthermore, **5** significantly reduced lipofuscin bisretinoid accumulation and normalized complement system protein expression in the retinal pigment epithelium (RPE) of *Abca4*^{-/-} mice, a model that recapitulates the phenotype of Stargardt disease.²⁸

Buoyed by the in vitro and in vivo profiles of **5**, we sought to further build upon our findings and expand our compound portfolio by developing additional structurally diverse series of RBP4 antagonists. Our objective was to identify novel chemical matter devoid of carboxylic acid. Carboxylic acids are present in numerous drugs, and our earlier RBP4 antagonists utilized this functional group effectively. Carboxylic acids can confer numerous benefits, such as reducing CNS exposure; however, some carboxylic acid-bearing compounds have also been reported to present idiosyncratic drug toxicity liabilities that have been associated with acyl glucuronidation formation.²⁹ Thus, we sought to further expand our chemical matter portfolio by developing diverse series that could avoid potential acyl glucuronidation liabilities should they arise. Drawing from the reported *N*-benzyl imidazole RBP4 antagonist **6** (*h*RBP4 scintillation proximity assay (SPA) IC₅₀ = 0.44 ± 0.18 μM)³⁰ (Figure 2) and guided by our previously reported 3FMZ-derived computational docking model,^{26,27} we implemented a structure–activity relationship (SAR) strategy involving the design and synthesis of novel compounds presenting 2- and 3-carboxamido-fused [5,6]-bicyclic heteroaromatic “bottom group” appendages. Our goal was to reduce the number of rotatable bonds of **6** by fusing the pendent benzyl group phenyl ring directly to the imidazole ring via a [5,6]-bicyclic heteroaromatic framework. We hypothesized that motifs that remove these rotatable bonds but still project an aromatic ring toward the opening of the binding pocket may provide novel chemical matter with improved potency and physicochemical properties relative to **6**.

Figure 3 highlights how we initially executed our medicinal chemistry work plan. Novel analogues were synthesized with the 4-(2-(trifluoromethyl)phenyl)piperidine core scaffold of **3** and in some cases, with the bicyclic core system of **4** and **5**. We began our campaign by exploring 3-carboxamides of various fused bicyclic heteroaromatic systems appended to both cores followed by subsequent syntheses of analogues bearing 2-carboxamido-fused bicyclic heteroaromatic systems. Select piperidine core analogues bearing a 3-carboxamido [1,2,4]-triazolo[4,3-*a*]pyridine-6-carbonitrile bottom group motif with alternatively fluorinated 2-trifluoromethylphenyl head groups were also later prepared.

CHEMISTRY

The syntheses of compounds possessing 1*H*-indazole-3-carboxamides (**11**–**18**) are presented in Scheme 1.³¹ Tertiary alcohol **8** is manufactured via addition of lithiated **7** to *N*-benzyl-4-piperidinone. Elimination of **8** upon treatment with thionyl chloride yields

tetrahydropyridine **9**, which was reduced and *N*-benzyl deprotected in a one-pot transformation via Pd/C-catalyzed ammonium formate reduction. Treatment of the resultant piperidine freebase with HCl provided hydrochloride salt **10**, which underwent facile amide formation with various 1*H*-indazole-3-carboxylic acids to generate amide analogues **11–18** using 2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetra-methyluronium hexafluorophosphate (HBTU) as the peptide coupling agent.

The syntheses of N1-substituted-1*H*-indazole-3-carboxamides **19–21** are highlighted in Scheme 2. Alkylation of 1*H*-indazole **13** with either iodoethane or 2-iodopropane gave **19** and **20**, respectively. Formation of desired oxetane **21** was achieved via alkylation between **13** and iodooxetane.

The syntheses of benzo[*d*]isoxazole-3-carboxamide **22** and benzo[*c*]isoxazole-3-carboxamide **23** are depicted in Scheme 3. HBTU-facilitated peptide coupling of benzo[*d*]isoxazole-3-carboxylic acid or benzo[*c*]isoxazole-3-carboxylic acid with piperidine hydrochloride **10** afforded **22** and **23**, respectively.

We previously disclosed the synthesis of bicyclic intermediate **31**, which is highlighted in Scheme 4.³² Reduction and subsequent *N*-Boc protection of dione **24** gave unsaturated isoindole **25**, which underwent oxidative cleavage to provide diacid **26**. Dieckman condensation followed by decarboxylation gave ketone intermediate **27**, which was converted to racemic vinyl triflate ($\pm$)-**28**. Compound ($\pm$)-**28** underwent a Pd-catalyzed Suzuki cross-coupling reaction to give styrene ($\pm$)-**29**, which underwent Pd/C-catalyzed hydrogenation to provide endo-isomer **30** exclusively. *N*-Boc deprotection with 2.0 M HCl in Et₂O afforded hydrochloride salt **31**.

[1,2,4]Triazolo[4,3-*a*]pyridine analogues **34–43** were accessed via the synthetic routes presented in Scheme 5. Triazolo[4,3-*a*]pyridine-3-carboxylic acids **33a–e** were produced in two steps via initial condensation of ethyl 2-oxoacetate with 5-substituted 2-hydrazinylpyridines **32a–e** followed by a PhI(OAc)₂-mediated ring cyclization. The carboxylic acids **33a–e** subsequently underwent amide formation with intermediates **10** and **31** to afford the desired analogues **34–43**.

Acid **44** served as an access point for both piperidine and bicyclic-containing core analogues **48–53**. HBTU-mediated peptide coupling between **44** and amines **10** and **31** furnished compounds **45** and **46**, respectively. These intermediary aryl bromides were converted to the nitrile-bearing analogues **48** and **51** via Pd-catalyzed cyanation with Zn(CN)₂. Methylation of **45** to provide **49** was achieved with Fe(acac)₃ and CH₃MgBr. Analogue **52** was obtained via carbonylation of **46** with Mo(CO)₆ in CH₃OH followed by hydrolysis of the resulting methyl ester with LiOH·H₂O. Urea **53** was furnished via Pd-catalyzed amination between **46** and *N,N*-dimethylurea. The synthesis of sulfonamide analogue **54** began with a Pd-catalyzed carbon–sulfur cross-coupling between **46** and benzyl thiol to furnish an intermediary benzyl mercaptan, which was then converted to the sulfonyl chloride and treated with *N*-methylamine (Scheme 6).

A subset of analogues presenting alternatively fluorinated 2-trifluoromethylphenyl groups was designed to further explore the hydrophobic β -ionone binding pocket of RBP4 (**59**, **62**, **63**, and **65**) (Schemes 7 and 8). The preparation of fluorinated analogue **59** is depicted in Scheme 7. Conversion of **55** to vinyl triflate **56** was followed by Pd-catalyzed Suzuki cross-coupling to furnish tetrahydropyridine **57**. Hydrogenation of **57** followed by *N*-Boc deprotection with 2.0 M HCl in Et₂O provided piperidine hydrochloride salt **58**. HBTU-mediated peptide coupling between **58** and carboxylic acid **44** followed by Pd-catalyzed cyanation with Zn(CN)₂ afforded the desired analogue **59**.

The preparation of fluorinated analogues **61**, **62**, and **64** is shown in Scheme 8. Suzuki cross-coupling between vinyl triflate **56** and (5-fluoro-2-(trifluoromethyl)phenyl)boronic acid or (4-fluoro-2-(trifluoromethyl)phenyl)boronic acid followed by *N*-Boc deprotection gave intermediary tetrahydropyridines **60a** and **60b**, respectively. PtO₂-mediated hydrogenation of these tetrahydropyridines gave corresponding piperidine intermediates that readily underwent amide formation with **44**. Cyanation of these amides using the aforementioned Pd-catalyzed conditions with Zn(CN)₂ yielded **61** and **62**, respectively. The synthesis of fluorinated aryl head group analogue **64** followed a route previously described for the preparation of compound **59** with the exception that tetrahydropyridine hydrogenation to give piperidine intermediate **63** was conducted with PtO₂ under 1 atm instead of 10% Pd/C at 30 psi of H₂. *N*-Boc deprotection of **63** followed by peptide coupling with **44** and subsequent Pd-catalyzed cyanation led to the desired compound **64**.

The syntheses of various 2-carboxamido-fused [5,6]-bicyclic heteroaromatic analogues (**65**–**72**) are highlighted in Scheme 9. These analogues were prepared by peptide coupling between the respective heteroaromatic 2-carboxylic acid and **10** in the presence of HBTU.

The syntheses of a series of follow-up 6-substituted imidazo[1,2-*b*]pyridazine-2-carboxamide analogues (**74**–**78**) were generated from key intermediate **73**, as depicted in Scheme 10. Methylation of **73** to give **74** was achieved via Pd(dppf) cross-coupling with trimethylboroxine. Nucleophilic aromatic substitution of **73** with NaOCH₃ provided methoxy analogue **75**. The installation of the cyclopropyl ring of **76** was achieved via a Pd(OAc)₂ cross-coupling reaction with **73** and potassium cyclopropyltrifluoroborate in the presence di-(1-admantyl)-*n*-butylphosphine and Cs₂CO₃. Lastly, heating **73** in neat pyrrolidine or morpholine yielded the desired nucleophilic aromatic substitution products **77** and **78**, respectively.

RESULTS AND DISCUSSION

The reported PDB high-resolution X-ray crystal structures 3FMZ (cocrystal structure of **3** bound to RBP4)^{30,33} and 4PSQ (cocrystal structure of **6** bound to RBP4)³⁰ provided critical data that was used in support of our structure-based drug design efforts toward novel fused [5,6]-bicyclic heteroaromatic amide-containing analogues (Figure 4). The structural data show **3** and **6** binding within the internal binding cavity of RBP4 with similar geometric alignment. The core piperidine ring of **3** and piperazine ring of **6** both reside in the relatively narrow β -barrel channel of the binding cavity and their respective 2-substituted aryl head groups projecting into the vacuous and hydrophobic β -ionone pocket where van der Waals

contacts are made (Figure 4). The urea of **3** and the carboxamide of **6** both accept an H bond from backbone amide Leu37. A salt bridge forms between the carboxylic acid of **3** and Arg121 toward the opening of the binding pocket (Figure 4A). Furthermore, two key H bonds are also established between the acid of **3**, Tyr90, and Gln98 whereas the phenyl ring of **3** also engages in an edge-to-face π - π binding interaction with Phe96. In contrast, the N2 imidazole nitrogen of **6** engages in an H bond with the Arg121 η NH₂ group whereas the *N*-benzyl appendage projects toward the opening of the binding cavity (Figure 4B). The key H-bond binding interactions with Leu37 and Arg121 described for **3** and **6** are hypothesized to play a crucial role in the induction and stabilization of conformational changes within RBP4 loops β 3- β 4 and β 5- β 6 that prohibit complexation between RBP4 and TTR and afford antagonist functional activity.^{14,21,22,30}

As previously reported, 3FMZ data was employed to construct a computational docking model (version 5.8, Schrodinger, LLC.), which was used to triage novel analogue proposals prior to synthesis by identifying compounds that were predicted to have good docking orientations within the RBP4 binding cavity. The docking and analysis of novel analogues in our 3FMZ data model of RBP4 was performed as previously described.^{26,27}

Drawing from the *N*-benzyl imidazole motif of **6**, we hypothesized that analogues presenting carboxamides of fused [5,6]-bicyclic heteroaromatic systems could also serve to position key H-bond accepting groups within close proximity to Arg121 and Leu37. Furthermore, such motifs remove the rotatable bonds of the *N*-benzyl appendage of **6** but still project an aromatic ring toward the opening of the binding pocket, which may provide analogues with improved potency and physicochemical properties. Indeed, our initial 3FMZ docking experiment with 3-carboxamido-1*H*-indazole **11** predicted that the N2 nitrogen of the 1*H*-indazole ring H-bonds with Arg121 whereas the carboxamide carbonyl oxygen would serve as an H-bond acceptor with Leu37 (Figure 5). Encouraged by the docking result for **11**, we synthesized a sample set of 1*H*-indazole (**11–21**)- and benzisoxazole (**22** and **23**)-containing analogues.

In Vitro Binding of Compounds to RBP4.

Binding affinities for RBP4 were measured using our scintillation proximity assay (SPA), as previously reported.^{26–28,34} Binding experiments were performed on white 96-well plates in a final assay volume of 100 μ L/well. The reaction mixture contained 10 nM ³H-retinol (48.7 Ci/mmol; PerkinElmer), 0.3 mg/well streptavidin-poly(vinyl toluene) beads, and 50 nM RBP4 labeled with biotin. The SPA buffer contained 1 $\times$ phosphate-buffered saline (PBS), pH = 7.4, 1 mM ethylenediaminetetra-acetic acid, 0.1% bovine serum albumin, and 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate. Nonspecific binding was measured in the presence of 20 μ M cold (unlabeled) retinol. Using these assay conditions, saturation binding of retinol to RBP4 afforded a *K*_d of 62.5 nM, which is in line with the previously reported 70–190 nM range of values. For compound characterization, competitive displacement of ³H-retinol was measured. The concentration of ³H-retinol was 10 nM, which corresponds to the generally recommended concentration of radioligand (1/10 of the *K*_d). The IC₅₀ values were calculated from eight-point compound titrations using four-parameter nonlinear regression in Graph-Pad Prism (version 8). Compounds with

appreciable RBP4 binding potency (generally, with $IC_{50} < 150$ nM) were further assessed for their ability to inhibit the retinol-dependent RBP4–TTR interaction using a homogenous time-resolved fluorescence (HTRF) assay.^{26–28,34}

Antagonism of RBP4–TTR Interaction HTRF Assay.

The ability of the compounds to disrupt the retinol-induced interaction of RBP4 with TTR was examined using our HTRF assay, as described previously.^{26–28,34} Bacterially expressed maltose binding protein (MBP)-tagged RBP4 and Eu^{3+} -cryptate-labeled commercially available human TTR were used along with a d2-conjugated anti-MBP monoclonal antibody. Retinol at 1 μ M concentration stimulates the formation of the RBP4–TTR complex, which brings europium in close proximity to the d2 dye, resulting in the fluorescence energy transfer (FRET) to d2. The FRET emission signal (668 nm) was normalized using the europium emission (620 nm) to compensate for the pipetting and dispensing errors. Following a 12-point dose titration (30 μ M to 0.1 nM), the IC_{50} values were calculated using four-parameter nonlinear regression in GraphPad Prism (version 8). To monitor the correlation between RBP4 binding affinity of the compounds and their potency as antagonists of the retinol-dependent RBP4–TTR interaction, the ratio of their IC_{50} values in the HTRF and SPA assays was tracked. For most compounds, a ratio in the 5–20 range was observed, despite the differences in their binding affinities.

Analogue SAR.

1*H*-Indazole-3-carboxamide analogues containing substituents at the 5-, 6-, and 7-position of the 1*H*-indazole ring (**11** and **13–18**) and on the N1 nitrogen atom (**12** and **19–21**) were initially prepared from piperidine hydrochloride **10**. In vitro RBP4 potency, kinetic aqueous solubility, and liver microsomal metabolic stability for these compounds are shown in Table 1. The majority of these analogues exhibited excellent in vitro potency in the RBP4 SPA and HTRF assays. 1*H*-Indazole **11** presented an approximate 2-fold improvement in RBP4 SPA binding affinity relative to benchmark **3** and a nearly 3-fold improvement in HTRF functional antagonist activity. Substitution with either F or Cl at the 5-, 6-, or 7-position of the 1*H*-indazole ring (**13–16** and **18**) provided analogues of comparable potency to parent **11**. However, installation of an OCH_3 group at the 5-position (**17**) significantly diminished RBP4 SPA and HTRF potency. It is unclear whether the increased steric bulk, polarity, or the electron-donating capability of the OCH_3 group (or any combination thereof) contributed to the loss of potency observed for **17** relative to **13–16** and **18**.

The N1 1*H*-indazole nitrogen also provided a handle with which to install various groups that could further probe the RBP4 binding cavity. Methylation to give **12** neither improved nor diminished in vitro RBP4 potency relative to parent **11**, whereas increasing the bulk of the N1 substituent from methyl to ethyl (**19**) and isopropyl (**20**) significantly reduced potency. Interestingly, installation of the N1 oxetane appendage (**21**) restored potency comparable to **12**. Lastly, isosteric benzisox-azoles **22** and **23** were also found to be of comparable potency to **11**. The favorable in vitro RBP4 potencies observed for this initial sample set confirmed that fused [5,6]-bicyclic systems may be viable replacements for the carboxylic of **3** and **5** and the *N*-benzyl imidazole of **6**. However, enthusiasm for this series was tempered as the compounds generally exhibited very poor kinetic aqueous solubility or

poor microsomal metabolic stability (or both), which was likely attributable in part to their relatively high lipophilicity and suboptimal lipophilic ligand efficiency (LLE) (RBP4 SPA $\text{pIC}_{50} - \text{cLog } P$).³⁵

We next explored less lipophilic [1,2,4]triazolo[4,3-*a*]-pyridine-3-carboxamides with the piperidine core of **10** (**34–38**, **48**, and **49**) and the bicyclic core of **31** (**39–43** and **50–53**). Data for these compounds are highlighted in Table 2. We were encouraged to find that the [1,2,4]triazolo[4,3-*a*]pyridine motif afforded antagonists with excellent in vitro potency. Importantly, a direct comparison of the fluorinated 1*H*-indazole **15** with its less lipophilic congener **34** revealed that the latter exhibits comparable SPA potency, improved HTRF potency, and improved LLE (**15** LLE = 4.41; **34** LLE = 5.45). Indeed, the [1,2,4]triazolo[4,3-*a*]pyridine series as a whole demonstrated a general improvement in LLE trends relative to the previous 1*H*-indazole series, which also correlated with improved solubility and metabolic stability for compounds within this sample set, as exemplified by nitrile **48** (LLE = 6.08).

Exploration of aryl head group SAR for standout analogue **48** was conducted with a focused set of fluorinated 2-trifluoromethylphenyl bearing analogues (**59**, **61**, **62**, and **64**) (Table 3). All of the compounds of this sample set presented in vitro RBP4 SPA potency comparable to des-fluoro parent **48**. However, with the exception of **64**, the fluorinated analogues exhibited an approximate 3-fold improvement in HTRF potency. Furthermore, fluorination ortho or meta to the 2 trifluoromethyl group did not diminish kinetic solubility relative to **48** whereas para fluorination led to a precipitous drop in solubility. Lastly, unlike **61**, **62**, and **64**, analogue **59** maintained a favorable microsomal metabolic stability profile across multiple species and it quickly emerged as a lead.

Docking of **48** and **59** into our 3FMZ computational model showed both compounds extending their respective aryl head groups into the hydrophobic β -ionone cavity where they orient themselves into a nearly orthogonal position relative to their corresponding piperidine rings (Figure 6). The carboxamides for both compounds serve as H-bond acceptors for Leu37, and their respective [1,2,4]triazolo[4,3-*a*]pyridine N2 nitrogen atoms are engaged in H-bond interactions with Arg121. We postulate that the 3-fold improvement in RBP4 HTRF potency observed for fluorinated **59** relative to **48** may be due in part to additional van der Waals contacts within hydrophobic β -ionone cavity, which may serve to better secure the compound within the binding pocket and allow for more stabilized H-bond interactions with Leu37 and Arg121.

We next explored the effects of repositioning heteroaryl amide connectivity by preparing compounds featuring a 2-carboxamido fused [5,6]-bicyclic heteroaromatic moiety (**65–72**) (Table 4). The RBP4 SPA potencies of benzimidazole **65**, benzoxazole **66**, and benzothiazole **67** were all within 2-fold of **48** and **59**; however, all three compounds exhibited significantly diminished potency in the HTRF assay. Benzoxazole **66** also exhibited low solubility and poor microsomal metabolic stability. Indole analogue **68** presented RBP4 binding affinity that was within 3-fold of **48** and **59**, but its HTRF potency was diminished by nearly 2 orders of magnitude. Interestingly, the specific placement of an additional nitrogen atom within the indole ring to give azaindoles **69** and **70** had a dramatic

effect on HTRF potency. Placement of a nitrogen atom at the 6-position of the indole ring to give azaindole **69** resulted in a 5-fold loss in RBP4 binding affinity and a 2-fold loss in HTRF potency compared with parent indole **68**. However, placement of a nitrogen at the 4-position to give the azaindole congener **70** restored binding affinity while significantly improving HTRF potency relative to **68**. Our docking model suggests that the position of the indole ring nitrogen of **70** brings it within closer proximity to Gln98 and a putative structural water in the binding site relative to the nitrogen of **69**, resulting in more stable H bonds (Figure 7). However, despite the intriguing activity of **70**, the compound exhibited very poor kinetic solubility and metabolic stability. Lastly, we also explored analogues incorporating 2-carbox-amido imidazo[1,2-*a*]pyridine-(**71**) and imidazo[1,2-*b*]pyridazine (**72**) moiety. Both compounds exhibited comparable RBP4 SPA binding affinity; however, **71** was 10-fold more potent than **72** in the HTRF assay. Despite the poor metabolic stability observed for **72**, we were encouraged by its excellent RBP4 potency and proceeded to explore a small sample set of follow-up analogues.

Table 5 highlights the additional imidazo[1,2-*b*]pyridazine-2-carboxamide analogues prepared (**74–78**). All five compounds presented robust RBP4 potency in the SPA binding assay, and analogues **74** and **75** also displayed exceptional potency in the HTRF assay. Within this series, morpholine **78** presented a favorable balance of RBP4 potency, solubility, and metabolic stability.

Encouraged by the excellent RBP4 potency, suitable kinetic solubility and good microsomal stability, previously described **48** and **59** were further studied in a battery of preclinical ADME studies. Their in vitro pharmacological profiles are shown in Table 6. Both **48** and **59** presented low microsomal CL_{int} for human, dog, and cynomolgus monkey liver microsomes with moderate CL_{int} for rat. Both compounds did not exhibit appreciable potency in a standard cytochrome P450 (CYP) inhibition panel (all CYP inhibition IC₅₀ > 4.7 μM), and their corresponding percent plasma protein binding (%PPB) values are in an optimal range and indicate a relatively low fraction unbound.

Compounds **48** and **59** were devoid of ancillary activity at the hERG channel or CYP-induction liabilities in the pregnane × receptor (PXR) activation assay (Table 7). Both compounds showed no signs of genotoxicity and mutagenicity in the Ames study. In a CEREP screening panel comprising 55 GPCRs, enzymes, ion channels, and transporters, **48** exhibited weak activity at the κ-opioid receptor (KOR) with an EC₅₀ = 4 μM. Conversely, compound **59** did not display any off-target pharmacology at KOR or at any other target within the screening panel. Lastly, both compounds were highly permeable in the MDR1–MDCK assay.

Additional in vitro CYP experiments revealed that **48** and **59** demonstrate moderate time-dependent inhibition (TDI) at CYP2D6. IC₅₀ determinations with or without a preincubation step preceding the coincubation of the test compound, a CYP-selective substrate, and human liver microsomes (HLM) were conducted in parallel for each compound. Two preincubation arms of the assay were conducted: (1) one arm involves test compound incubated with HLM in the absence of NADPH ((–)NADPH), and (2) a second arm involves the test compound incubated with HLM in the presence of NADPH ((+)NADPH) (Table 7). A 16- and 20-fold

leftward shift was observed in the (+)NADPH IC₅₀ curve relative to the (–)NADPH IC₅₀ curve for compounds **48** and **59**, respectively. The inactivation parameters K_I , k_{inact} , and k_{inact}/K_I were next determined for both compounds to better characterize their inhibitory potential at CYP2D6.³⁶ The values of k_{inact} and K_I were determined by incubating different concentrations of the test compounds with human liver microsomes in the presence of NADPH over a specific time course, and these values are captured in Table 7. The k_{inact} values for both compounds were low and the K_I values were orders of magnitude higher than the respective RBP4 SPA and HTRF IC₅₀ values for each compound. Taken collectively, the k_{inact}/K_I data suggest that both compounds are TDI-negative and do not pose a risk as a perpetrator of CYP2D6-mediated drug–drug interactions.

In Vivo Activity: PK Characteristics of 48 and 59 in Rodents.

Both **48** and **59** possessed favorable PK profiles in naïve male CD-1 mice and adult Sprague-Dawley male rats (Table 8). The compounds exhibited moderate to low clearance and good half-lives ($t_{1/2}$) in both species. Adequate exposures (AUC_{last}) and good oral bioavailability (%F) were also achieved. The good oral bioavailability, moderate half-lives, and decent exposures achieved in mice coupled with favorable ADME profiles fully justified the use of **48** and **59** to establish PK/PD and ultimately proof-of-concept in murine animal models.

In Vivo Activity: PK/PD Correlations of Compound 59 in Mouse.

Before testing **59** in the murine transgenic model of hepatic steatosis, we conducted acute dosing studies with **59** in mouse to measure the compound's effect on circulating plasma RBP4 levels and to establish PK/PD correlations (Figure 8). After a single oral dose of **59** (5 mg/kg), 85% maximal reduction in plasma RBP4 was observed (Figure 8A), whereas plasma RBP4 was decreased by 81% following a 2 mg/kg intravenous dose (Figure 8B). In vivo serum RBP4 lowering after both oral and intravenous dosing of **59** (Figure 8A,B) showed a good correlation with the compound concentration in plasma (Figure 8C,D). The long exposure and moderate to low clearance of **59** achieved after a single oral dose (Table 1) correlated well with the extent of the RBP4 reduction (85% reduction at the 12 h time point) and the duration of the RBP4 lowering effect (71% reduction at the 24 h time point). Furthermore, the magnitude of RBP4 lowering correlated very well with the projected free drug concentration of **59** in the plasma, which exceeded that required for disrupting the RBP4–TTR interaction measured in the in vitro HTRF assay. This data confirms in vivo target engagement for **59** and reveals an excellent PK/PD relationship between compound exposure and biological response in mice, additionally justifying characterization of **59** in the mouse transgenic model of hepatic steatosis.

Analogue 59 Reduces Circulating Levels of Adipose-Derived RBP4 in the Mouse Transgenic Model of Hepatic Steatosis.

As reported previously by Blaner and co-workers,²² the mouse genetic model of hepatic steatosis was generated by targeting the human RBP4 (hRBP) cDNA construct with a loxP-neo^r-stop cassette to the mouse Rosa26 locus. To specifically express hRBP4 in mouse adipocytes, knock-in mice were bred with adiponectin-Cre mice.²² Specific expression of

human RBP4 in mouse adipocytes yielded no significant elevation in the circulating levels of RBP4 and no changes in retinoid levels in plasma, liver, and adipose tissue while inducing obesity, impaired glucose tolerance, and pronounced increase in hepatic triglyceride (TG) levels.²² To examine the effect of **59** on metabolic parameters in male adi-hRBP4 mice, we administered the compound as a formulation into the HFD chow at a dose of 20 mg/kg per day for 29 days. Compound administration started at 20 weeks of age when the animals were switched from a standard chow to a high-fat diet (60% of calories from fat). Chronic oral administration of **59** induced a 90% decrease in circulating levels of both mouse and human (adipose tissue-secreted) serum RBP4 (Figure 9). In untreated adi-hRBP4 mice, circulating levels of adipose-derived human RBP4 (2–3 $\mu\text{g/mL}$) represented a small 3–5% fraction of mouse-specific serum RBP4 produced predominantly in the liver (Figure 9). Remarkably, this modest increase in circulating levels of RBP4 conferred by adipocyte secretion was sufficient to trigger the induction of the strong metabolic phenotype.

Analogue 59 Reduces Body Weight Gain in Obese adi-hRBP4 Mice.

Over the 29 day study period, the adi-hRBP4 mice on high-fat diet gained significantly more weight than transgenic animals kept on a standard chow (Figure 10A). A statistically significant difference between the chow-fed and HFD adi-hRBP mice in percent weight gain was evident 5 days after initiation of the high-fat feeding (Figure 10A). Body weight gain in HFD animals was significantly reduced by administration of analogue **59**. A statistically significant difference in body weight gains between **59**-treated and untreated HFD mice was evident after 19 days of high fat diet feeding (Figure 10A). At the end of the 29 day treatment period, the mean body weight gain in the **59**-treated animals (2.2 ± 1.7 g) was 53% less than in the untreated animals on HFD (4.7 ± 1.6 g). Reduction in the body weight gain in **59**-treated adi-RBP4 mice was not associated with decreased food intake as **59** did not alter consumption of the HFD chow (Figure 10B).

Reduction of Hepatic Lipid Levels by Analogue 59 in Obese adi-hRBP4 Mice.

In accordance with the previous report,²² hepatic free fatty acid (FFA) and triglyceride (TG) levels in adi-hRBP4 mice maintained on the high-fat diet were significantly higher than in transgenic animals kept on a standard chow (Figure 11; $P < 0.0001$ for both FFA and TG). Administration of **59** lowered the FFA levels by 30% (Figure 11A; $P = 0.0107$) and TG levels by 29% (Figure 11B; $P = 0.0104$).

Consistent with the dynamics of hepatic TG accumulation, histological examination of oil red O-stained frozen liver sections (Figure 12A) and hepatic steatosis grading (Figure 12B) confirmed significantly more steatosis in adi-hRBP4 mice maintained on HFD in comparison to the chow-fed transgenic mice, which showed no evidence of hepatic steatosis. Significant improvement in hepatic steatosis was seen in the **59**-treated adi-hRBP4 obese mice, which exhibited fewer and smaller lipid droplets in comparison with the untreated adi-hRBP4 mice maintained on HFD (Figure 12A). Hepatic steatosis grading (Figure 12B) revealed a significant 43% reduction in the degree of steatosis in **59**-treated HFD-fed adi-hRBP4 mice ($P < 0.001$), which further confirmed the ability of **59** to alleviate hepatic steatosis in adi-hRBP4 mice.

Binding of Fatty Acid Ligands to RBP4.

Blaner and coworkers reported that hepatic steatosis observed in the adi-hRBP4 mouse model results from the increased mobilization of fatty acids from adipose tissue, which led to elevation in plasma levels of fatty acids and enhanced hepatic uptake of circulating free fatty acids.²² It remains unclear how the modestly increased expression of RBP4 in adipose tissue contributes to the development of hepatic steatosis. One can surmise that this ability of RBP4 may relate to binding and trafficking of endogenous nonretinoid ligands, the nature and abundance of which is unknown at this point. Consistent with the ability of RBP4 to interact with nonretinoid ligands, previous crystallographic studies of heterologously expressed RBP4 revealed fortuitous fatty acid ligands from the expression host (oleic acid and linoleic acid) bound within the ligand-binding pocket of RBP4.^{23,24} Recent X-ray crystallographic and mass spectrometry findings reported by Monaco and coworkers confirmed that RBP4 is capable of binding fatty acids.²⁵ The capacity of retinol-binding proteins to bind hydrophobic nonretinoid ligands may be general, as illustrated by recently described interactions of cellular retinol-binding protein 1 with certain cannabinoids.³⁷ We tested the affinity of palmitic acid, oleic acid, linoleic acid, and docosahexaenoic acid for RBP4 using a SPA assay³⁴ that measures displacement of radioactive retinol from purified human RBP4 (Figure 13A). These competition binding experiments confirmed the ability of the tested fatty acids to function as weak RBP4 ligands. Our docking model is also consistent with the ability of RBP4 to bind fatty acid ligands. Figure 13B presents overlays of **48** and the fatty acids palmitic acid, oleic acid, linoleic acid, and docosahexaenoic acid docked within our 3FMZ model and of **1** docked within our 5NU7 (holo-RBP4) model. The figure shows a good overlay between **1** and **48** as both present similar geometric poses and project their polar fragments toward the opening of the binding cavity where they engage in H-bond interactions with Gln98 and Arg121, respectively. Similar to **1** and **48**, the fatty acids also extend their hydrophobic tails through the narrow β -barrel and into the β -ionone pocket and their polar carboxylic acids bind to residues residing closer to the opening of the binding cavity, namely, Leu36 and Phe36.

CONCLUSIONS

Epidemiologic evidence suggests that elevated circulating levels of RBP4 may have significant metabolic effects. Nonretinoid RBP4 antagonists represent an important pharmacological tool for assessing the role of RBP4 in pathogenesis of metabolic disorders, such as NAFLD and NASH. We previously reported efforts to develop novel RBP4 antagonists using **3** and 3FMZ as springboards for our structure-based drug design strategies. Our investigations ultimately led us to discover the bicyclic antagonists **4** and **5**. However, in addition to exploring analogues with isosteric replacements for the piperidine core of **3**, we also sought to investigate novel appendages that did not bear a carboxylic acid group. Drawing from compound **6** and 4SPQ, we investigated various 2- and 3-carboxamido-fused [5,6]-biaryl heteroaromatic systems that featured either a piperidine or bicyclic core to which the *ortho*-trifluoromethyl-phenyl head group of **3** was retained. Of these diverse sets of compounds, **48** was selected as the lead compound displaying unique in vitro RBP4 potency, good solubility, and robust in vitro microsomal stability. Focused SAR exploration of the aryl head group afforded analogue **59**, which displayed a similar profile to

48 but with improved HTRF potency. Analogues **48** and **59** were subjected to detailed in vitro and in vivo evaluation and displayed favorable ADME profiles, no deleterious off-target binding in vitro, and excellent PK properties in rodents. Consistent with its good PK properties, **59** induced a robust 80–85% plasma RBP4 reduction after administration of a single oral or intravenous dose in mice (Figure 8). A general safety concern for the class of RBP4 antagonists exemplified by analogue **59** is whether such a profound reduction in serum RBP4 may induce symptoms of systemic vitamin A deficiency. On the basis of the available evidence, pharmacological downregulation of serum RBP4 cannot be considered analogous to systemic deprivation of vitamin A. Whereas RBP4–TTR complex is the major trafficking system for retinol delivery to vitamin A-dependent tissues, retinoid delivery to organs can occur via several complementary RBP4-independent pathways.^{38–43} Following the absorption of **1** in the gut, dietary retinoids are incorporated into chylomicrons, which transport retinoids predominantly to the liver. However, extrahepatic vitamin A-dependent tissues are responsible for the uptake of about 25–33% of postprandial retinoid-laden chylomicrons.³⁸ Retinoic acid can also be delivered to the target organs in a complex with serum albumin.³⁹ In addition, biosynthesis of **1** from dietary β -carotene in RPE cells and other tissues has been reported.^{39,44} Patients with compound heterozygous missense mutations in RBP4 have plasma RBP4 levels below the limit of detection while showing no clinical symptoms of systemic vitamin A deficiency.⁴² *Rbp4*^{−/−} mice are phenotypically normal without systemic abnormalities^{38,40,41} or histological signs of retinal degeneration.⁴⁵ At weaning, *Rbp4*^{−/−} mice have reduced electroretinographic amplitudes, which completely normalize on standard chow that contains standard levels of **1**.^{38,40} Symptoms of vitamin A deficiency do not occur in TTR knock-out mice, despite low serum RBP4 levels and the absence of the circulating retinol–RBP4–TTR complex.⁴⁶ We recently reported that administration of analogue **5** at doses inducing 90% serum RBP4 lowering in mice partially reduced the level of retinoids in the retina and significantly inhibited bisretinoid synthesis without negatively affecting the rate of the visual cycle or inhibiting retinal function, as assessed by electroretinography.⁴⁷ In sum, pharmacological reduction of serum RBP4 by orally active RBP4 antagonists is unlikely to result in systemic vitamin A deficiency in patients who maintain a normal, vitamin A- and β -carotene-sufficient diet. Whereas adverse effects related to induction of systemic vitamin A deficiency are unlikely, the long-term use of the first-generation RBP4 antagonist fenretinide in cancer patients was associated with transient and reversible ocular side effects, such as diminished dark adaptation, in a small subset of patients (yearly prevalence: 5.8–6.7%).⁴⁸ For analogue **59** and related compounds, the balance between clinical efficacy and the extent of potential ocular adverse effects remains to be determined in future clinical trials.

Advanced ADME characterization of analogue **59** led to further studies in the mouse transgenic model of hepatic steatosis, adi-hRBP4 mice, in which a very modest 3–5% increase in circulated levels of RBP4 conferred by adipocyte secretion of human RBP4 was sufficient to trigger the induction of a strong metabolic phenotype. Chronic oral administration of **59** at a dose of 20 mg/kg per day induced a 90% decrease in circulating levels of both mouse RBP4 (produced predominantly in the liver) as well as human (adipose tissue-secreted) serum RBP4. Analogue **59** reduced the body weight gain in obese HFD-fed adi-hRBP4 mice by 53% without decreasing food intake. Hepatic free fatty acid and

triglyceride levels in adi-hRBP4 mice maintained on the high-fat diet were significantly higher than in transgenic animals kept on a standard chow. Administration of **59** lowered the hepatic FFA levels by 30% and TG levels by 29% in HFD-fed adi-hRBP4 mice. In accordance with the dynamics of hepatic TG accumulation, histological examination of frozen liver sections and hepatic steatosis grading confirmed significantly more steatosis in adi-hRBP4 mice maintained on HFD. Significant improvement in hepatic steatosis was seen in the **59**-treated adi-hRBP4 obese mice, which exhibited fewer and smaller lipid droplets than untreated HFD-fed adi-hRBP4 mice. Steatosis grading revealed a significant 43% reduction in the degree of steatosis in **59**-treated HFD-fed adi-hRBP4 mice. Taken collectively, these data confirmed the ability of **59** to alleviate hepatic steatosis in adi-hRBP4 mice, suggesting that RBP4 antagonist **59** may serve as a potential orally bioavailable pharmacotherapy for NASH. Consistent with the idea that adipose tissue-secreted RBP4 may potentially function as a transporter for endogenous hydrophobic ligands other than retinol, our competition binding experiments, supported by the docking model data, confirmed the ability of RBP4 to bind hydrophobic nonretinoid ligands, such as fatty acids. Synthetic RBP4 antagonists capable of suppressing hepatic lipid accumulation may be considered as a novel class of therapeutics for the treatment of NASH, particularly in patients with elevated circulating levels of RBP4.

EXPERIMENTAL SECTION

General Chemistry.

The reactions presented were conducted under an inert atmosphere of N₂ gas unless noted otherwise. Reactions indicating room temperature (rt) were conducted at 25 °C. Reagents and solvents acquired from commercial vendors were used as is. Rotary evaporations were conducted with Buchi rotary evaporators and Teflon-linked KNF vacuum pumps. AnalTech No. 02521 1 in. × 3 in. glass-backed silica gel plates with fluorescent indicator were used for routine thin-layer chromatography (TLC), and visualization of the plates was accomplished either via short wave UV light (254 nm lamp), 10% phosphomolybdic acid in ethanol or with iodine vapors. Analtech, 20 × 20 cm², 1000 μm preparative plates were used for compounds requiring preparative thin-layer chromatography for purification. Teledyne Isco CombiFlash Companion Unit was used for flash column chromatography. Teledyne Isco RediSep Rf silica gel columns were used for the stationary phase. In cases when reverse phase chromatography was required, a RediSep Gold C18 reverse phase column was employed. Proton NMR spectra were obtained either on a 300 MHz Bruker nuclear magnetic resonance spectrometer or 500 MHz Bruker nuclear magnetic resonance spectrometer and chemical shifts Bruker nuclear magnetic resonance spectrometer, and chemical shifts (δ) are reported in parts per million (ppm) and coupling constant (J) values are given in hertz, with the following spectral pattern designations: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet; br, broad. Tetramethylsilane was used as an internal reference. MEL-TEMP electrothermal melting point apparatus was used to generate reported melting points, which are uncorrected. Mass spectroscopic analyses were performed using the following: (1) electrospray ionization (ESI) ionization on a Varian ProStar LCMS with a 1200L quadrupole mass spectrometer; (2) ESI, atmospheric pressure chemical ionization (APCI), or DUIS ionization on a Shimadzu LCMS-2020 single

quadrupole mass spectrometer. High-pressure liquid chromatography (HPLC) purity analysis was performed using a Varian ProStar HPLC system with a binary solvent system A and B using a gradient elution [A, H₂O with either 0.05% or 0.1% trifluoroacetic acid (TFA); B, CH₃CN with either 0.05% or 0.1% TFA] and flow rate = 1 mL/min, with UV detection at either 223 or 254 nm. All final compounds tested for in vitro and in vivo biological testing were purified to 95% purity, and these purity levels were measured by using the following HPLC methods:

- A. Method A mobile phase: A = H₂O with 0.05% TFA and B = CH₃CN with 0.05% TFA; gradient: 0–90% B (0.0–20.0 min); UV detection was measured at 254 nm; method A column: 3.0 × 250 mm² Phenomenex C18(2) reverse phase column.
- B. Method B mobile phase: A = H₂O with 0.05% TFA and B = CH₃CN with 0.05% TFA; gradient: 0–90% B (0.0–20.0 min); UV detection was measured at 230 nm; method B column: 3.0 × 250 mm² Phenomenex C18(2) reverse phase column.
- C. Method C mobile phase: A = H₂O with 0.05% TFA and B = CH₃CN with 0.05% TFA; gradient: 0–100% B (0.0–20.0 min); UV detection at 254 nm; method C column: 4.6 × 250 mm² SunFire C18 5 μm reverse phase column.

(1H-Indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (11).—

Step A: To a solution of 1-bromo-2-(trifluoromethyl)benzene (**7**, 35.0 g, 156 mmol) in THF (350 mL) cooled to –78 °C was slowly added a solution of *n*-BuLi (70.4 mL, 2.5 M in THF, 176 mmol) over a period of 15 min. The mixture stirred at –78 °C for 40 min was allowed to warm to 0 °C and then cooled back down to –78 °C. To this was added a solution of 1-benzylpiperidin-4-one (22.1 g, 117 mmol) in THF (80 mL) over a period of 10 min. The resulting mixture was continued to be stirred at –78 °C for 2 h. The reaction was carefully quenched with aqueous, saturated aqueous NH₄Cl solution (500 mL), and the mixture was extracted with EtOAc (3 × 100 mL). The combined organic extracts were washed with H₂O, brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Isco CombiFlash Companion unit, 330 g RediSep column, 0–30% EtOAc in hexanes) to give 1-benzyl-4-(2-(trifluoromethyl)phenyl)piperidin-4-ol (**8**) as a light-yellow oil (29.2 g, 74%): ¹H NMR (500 MHz, CDCl₃) δ 7.78 (d, *J* = 1.6 Hz, 1H), 7.59 (m, 1H), 7.47 (m, 1H), 7.36 (m, 5H), 7.31 (m, 2H), 3.58 (s, 2H), 2.80 (m, 2H), 2.55 (m, 2H), 2.27 (m, 2H), 1.88 (m, 2H); MS (ESI+) *m/z* 336 [M + H]⁺.

Step B: A 0 °C cooled solution of 1-benzyl-4-(2-(trifluoromethyl)-phenyl)piperidin-4-ol (**8**, 29.2 g, 87.1 mmol) in SOCl₂ (60 mL) was stirred for 2 h and was then diluted with CH₂Cl₂ (250 mL). The mixture was carefully poured into a saturated aqueous NaHCO₃ solution (200 mL). The biphasic mixture was separated, and the aqueous layer was further extracted with CH₂Cl₂ (2 × 200 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The resulting residue was chromatographed over silica gel (Isco CombiFlash Companion unit, 330 g RediSep column, 0–30% EtOAc in hexanes) to give 1-benzyl-4-(2-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine (**9**) as a light-yellow oil (13.5 g, 49%): ¹H NMR (500 MHz, CDCl₃) δ 7.63 (d, *J* = Hz, 1H), 7.48 (m,

1H), 7.39 (m, 5H), 7.28 (m, 2H), 5.56 (s, 1H), (s, 2H), 3.14 (m, 2H), 2.70 (m, 2H), 2.39 (m, 2H); MS (ESI+) m/z 318 [M + H]⁺.

Step C: A mixture of 1-benzyl-4-(2-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine (**9**, 13.6 g, 42.5 mmol), 10% Pd/C (3.0 g), and HCO₂NH₄ (26.8 g, 425 mmol) in CH₃OH (800 mL) was heated at reflux for 2 h. The mixture cooled to rt and was filtered over Celite. The filtrate was concentrated, and the resulting residue was chromatographed over silica gel (Isco CombiFlash Companion unit, 330 g RediSep column, 0–10% CH₃OH with 1% NH₄OH in CH₂Cl₂) to give 4-(2-(trifluoromethyl)phenyl)piperidine as a colorless oil (2.0 g, 21%): ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, J = 1.7 Hz, 1H), 7.52 (m, 2H), 7.29 (m, 1H), 3.21 (m, 2H), 3.07 (m, 1H), 2.80 (m, 2H), 2.33 (bs, 1H), 1.77 (m, 4H); MS (ESI+) m/z 230 [M + H]⁺. To a solution of 4-(2-(trifluoromethyl)phenyl)piperidine (5.6 g, 24.5 mmol) in CH₃CN (30 mL) was added a 4 M solution of HCl in 1,4-dioxane (6.1 mL, 24.5 mmol) at rt. The mixture was stirred for 2 h and was then concentrated under reduced pressure to give 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (**10**) as a white solid (6.4 g, >99%): MS (ESI+) m/z 230 [M + H]⁺.

Step D: A mixture of 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (**10**, 0.115 g, 0.436 mmol), 1*H*-indazole-3-carboxylic acid (0.070 g, 0.436 mmol), Et₃N (0.18 mL, 1.308 mmol), and HBTU (0.248 g, 0.651 mmol) in DMF (5 mL) was stirred at rt for 16 h. The mixture was diluted with H₂O (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with H₂O (3 × 50 mL), brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (10–50% EtOAc in hexanes) to afford (1*H*-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (**11**) as a white solid (0.114 g, 70%): mp 175–177 °C; ¹H NMR (500 MHz, CDCl₃) δ 10.26 (bs, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.64 (m, 1H), 7.52 (m, 2H), 7.43 (m, 2H), 7.28 (m, 2H), (m, 2H), 3.28 (m, 2H), 2.98 (m, 1H), 1.85 (m, 4H); MS (ESI+) m/z 374 [M + H]⁺; HPLC 98.9% purity (AUC), t_R = 13.6 min (method A).

(1-Methyl-1*H*-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)methanone (12**).**—Compound **12** was prepared according to a similar procedure described for the synthesis of **11**. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, J = 7.8 Hz, 1H), 7.64 (m, 1H), 7.51 (m, 1H), 7.43 (m, 3H), 7.28 (m, 2H), 5.02 (m, 2H), 4.11 (s, 3H), 3.27 (m, 2H), 2.92 (m, 1H), 1.85 (m, 4H); MS (ESI+) m/z 388 [M + H]⁺; HPLC 98.4% purity (AUC), t_R = 14.8 min (method A).

(6-Fluoro-1*H*-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)methanone (13**).**—Compound **13** was prepared according to a similar procedure described for the synthesis of **11**. mp 210–212 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.54 (s, 1H), 8.4–8.01 (m, 1H), 7.71–7.60 (m, 3H), 7.44–7.39 (m, 2H), 7.13–7.10 (m, 1H), 4.96–4.78 (m, 2H), 3.25–3.17 (m, 2H), 2.92–2.90 (m, 1H), 1.82–1.77 (m, 4H); ESI MS m/z 392 [M + H]⁺; HPLC >99% purity (AUC), t_R = 10.5 min (method A).

(6-Chloro-1*H*-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)methanone (14**).**—Compound **14** was prepared according to a similar procedure

described for the synthesis of **11**. mp 221–223 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.64 (s, 1H), 8.2 (d, *J* = 8.7 Hz, 1H), 7.72–7.60 (m, 4H), 7.42 (t, *J* = 7.4 Hz, 1H), 7.26 (dd, *J* = 1.7, 8.7 Hz, 1H), 4.94 (d, *J* = 13.5 Hz, 1H), 4.79 (d, *J* = 12.1 Hz, 1H), 3.32–3.11 (m, 2H), 2.91 (t, *J* = 9.6 Hz, 1H), 1.89–1.70 (m, 4H); MS (APCI+) *m/z* 408, 410 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 15.4 min (method A).

(5-Fluoro-1H-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (15).—Compound **15** was prepared according to a similar procedure described for the synthesis of **11**. mp 188–190 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.64 (s, 1H), 7.73–7.59 (m, 5H), 7.45–7.39 (m, 1H), 7.36–7.29 (m, 1H), 5.08–4.99 (m, 1H), 4.83–4.74 (m, 1H), 3.29–3.13 (m, 2H), 2.95–2.85 (m, 1H), 1.86–1.71 (m, 4H); ESI MS *m/z* 392 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 10.5 min (method A).

(5-Chloro-1H-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (16).—Compound **16** was prepared according to a similar procedure described for the synthesis of **11**. mp 210–212 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.73 (s, 1H), 8.5 (s, 1H), 7.75–7.62 (m, 4H), 7.48–7.39 (m, 2H), 5.03 (d, *J* = 12.8 Hz, 1H), 4.79 (d, *J* = 11.8 Hz, 1H), 3.29–3.17 (m, 2H), 2.99–2.87 (m, 1H), 1.81 (t, *J* = 6.9 Hz, 4H); MS (APCI+) *m/z* 408, 410 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 15.6 min (method A).

(5-Methoxy-1H-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (17).—Compound **17** was prepared according to a similar procedure described for the synthesis of **11**. mp 168–170 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.75 (s, 1H), 7.69–7.62 (m, 3H), 7.42 (t, *J* = 6.3 Hz, 1H), 7.34 (d, *J* = 2.9 Hz, 1H), (d, *J* = 8.9 Hz, 1H), 7.22 (dd, *J* = 2.9, 8.9 Hz, 1H), 4.24 (d, *J* = 13.5 Hz, 2H), 3.79 (s, 3H), 3.09 (t, *J* = 11.4 Hz, 1H), 2.94 (t, *J* = 11.8 Hz, 2H), 1.86–1.68 (m, 4H); MS (APCI+) *m/z* 404 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 14.3 min (method A).

(7-Chloro-1H-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (18).—Compound **18** was prepared according to a similar procedure described for the synthesis of **11**. mp 192–195 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 14.03 (s, 1H), 7.98 (d, *J* = 8.2 Hz, 1H), 7.69 (d, *J* = 8.2 Hz, 2H), 7.64 (t, *J* = 7.4 Hz, 1H), 7.53 (d, *J* = 6.8 Hz, 1H), 7.42 (t, *J* = 7.8 Hz, 1H), 7.24 (t, *J* = 7.5 Hz, 1H), 4.87 (d, *J* = 13.0 Hz, 1H), 4.79 (d, *J* = 12.7 Hz, 1H), 3.29–3.16 (m, 2H), 3.03–2.83 (m, 1H), 1.89–1.70 (m, 4H); MS (APCI+) *m/z* 408, 410 [M + H]⁺; HPLC 99.4% purity (AUC), *t*_R = 11.4 min (method A).

(1-Ethyl-6-fluoro-1H-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (19).—To a solution of (6-fluoro-1*H*-indazol-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (**13**, 0.05 g, 0.13 mmol) and iodoethane (0.015 mL, 0.19 mmol) in DMF (2 mL) was added K₂CO₃ (0.044 g, 0.32 mmol). The mixture stirred for 4 h at rt and was then diluted with H₂O (5 mL). The aqueous mixture was extracted with EtOAc (3 × 5 mL), and the combined organic extracts were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (Parallax Flex unit, YMC-Pack ODS-A column, 5–95% CH₃CN in H₂O) to give (1-ethyl-6-fluoro-1*H*-indazol-3-yl)(4-(2-

(trifluoromethyl)phenyl)piperidin-1-yl)methanone as a white solid (0.020 g, 37%): mp 44–46 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.83 (dd, *J* = 2.4, 8.9 Hz, 1H), 7.64 (d, *J* = 7.7 Hz, 1H), 7.52 (t, *J* = 7.7 Hz, 1H), 7.46 (d, *J* = 7.9 Hz, 1H), 7.37 (dd, *J* = 4.0, Hz, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.20 (dt, *J* = 2.4, 8.9 Hz, 1H), 5.7 (d, *J* = 47.2 Hz, 2H), 4.44 (q, *J* = 7.3 Hz, 2H), 3.38–3.24 (m, 2H), 2.93 (br s, 1H), 1.99–1.81 (m, 4H), 1.54 (t, *J* = 7.3 Hz, 3H); MS (APCI +) *m/z* 420 [M + H]⁺; HPLC 97.0% purity (AUC), *t_R* = 16.6 min (method A).

(6-Fluoro-1-isopropyl-1H-indazol-3-yl)(4-(2-(trifluoromethyl)-

phenyl)piperidin-1-yl)methanone (20).—Compound 20 was prepared according to a similar procedure described for the synthesis of 19. mp 50–53 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.85 (dd, *J* = 2.4, 8.9 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.52 (t, *J* = 7.7 Hz, 1H), 7.46 (d, *J* = 7.8 Hz, 1H), 7.40 (dd, *J* = 4.0, 9.1 Hz, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.18 (dt, *J* = 2.5, 8.9 Hz, 1H), 5.09 (br s, 2H), 4.89–4.80 (m, 1H), 3.32–2.94 (m, 3H), 1.93–1.81 (m, 4H), 1.59 (d, *J* = 6.7 Hz, 6H); MS (APCI+) *m/z* 434 [M + H]⁺; HPLC 95.7% purity (AUC), *t_R* = 17.4 min (method A).

(6-Fluoro-1-(oxetan-3-yl)-1H-indazol-3-yl)(4-(2-

(trifluoromethyl)phenyl)piperidin-1-yl)methanone (21).—Compound 21 was prepared according to a similar procedure described for the synthesis of 19 using 3-iodooxetane and with heating at 60 °C for 24 h. mp 70–73 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.86 (dd, *J* = 2.2, 8.8 Hz, 1H), 7.65 (d, *J* = 7.8 Hz, 1H), 7.54–7.45 (m, 3H), 7.32 (t, *J* = 7.7 Hz, 1H), 7.23 (dd, *J* = 2.5, 8.9 Hz, 1H), 5.82–5.76 (m, 1H), 5.25 (t, *J* = 6.6 Hz, 2H), 5.16–5.11 (m, 3H), 5.02 (d, *J* = 12.1 Hz, 1H), 3.34–3.27 (m, 2H), 2.97–2.94 (m, 1H), 2.05–1.81 (m, 4H); MS (APCI+) *m/z* 448 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 15.4 min (method A).

Benzo[d]isoxazol-3-yl(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone

(22).—Compound 22 was prepared according to a similar procedure described for the synthesis of 11. ¹H NMR (500 MHz, CDCl₃) δ 7.94 (d, *J* = 7.8 Hz, 1H), 7.65 (m, 2H), 7.52 (m, 1H), 7.45 (m, 1H), 7.37 (m, 2H), 4.14 (m, 1H), 4.92 (m, 1H), 4.66 (m, 1H), 3.36 (m, 2H), 2.98 (m, 1H), 1.99 (m, 4H); MS (ESI+) *m/z* 375 [M + H]⁺; HPLC 96.7% purity (AUC), *t_R* = 15.4 min (method A).

Benzo[c]isoxazol-3-yl(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone

(23).—Compound 23 was prepared according to a similar procedure described for the synthesis of 11. mp 106–108 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.86 (d, *J* = 8.9 Hz, 1H), 7.45 (t, *J* = 9.1 Hz, 2H), 7.70–7.63 (m, 2H), 7.52–7.48 (m, 1H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.28–7.24 (m, 1H), 4.74–4.65 (m, 1H), 4.27–4.18 (m, 1H), 3.50–3.38 (m, 1H), 3.24–3.17 (m, 1H), 3.09–3.00 (m, 1H), 1.98–1.75 (m, 4H); MS (APCI+) *m/z* 375 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 12.1 min (method A).

(3aR,5r,6aS)-5-(2-(Trifluoromethyl)phenyl)octahydrocyclopenta-[c]pyrrole

Hydrochloride (31).—Step A: To a 0 °C cooled solution of LiAlH₄ (1.0 M, 800 mmol) in THF (800 mL) was carefully added (3aR,7aS)-3a,4,7,7a-tetrahydro-1*H*-isoindole-1,3(2*H*)-dione (24, 53.7 g, 0.35 mol) portionwise. An exotherm of ~5 °C occurred upon each addition of 24. Upon complete addition, the mixture was allowed to warm to rt followed by heating at

70 °C for 16 h. The mixture was allowed to cool back to rt and then further cooled to 0 °C. The reaction was carefully quenched by slow addition of H₂O (30 mL) and 15% aqueous NaOH solution (30 mL), followed by another bolus of H₂O (90 mL). The rate of quenching was done carefully so as to maintain an internal temperature below 25 °C. The mixture was stirred for 1 h and filtered through celite. The aqueous filtrate was extracted with Et₂O (2 × 100 mL), and the combined organic extracts were concentrated under reduced pressure. The resulting residue was purified using a Kugelrohr distillation apparatus to give (3a*R*, 7a*S*)-2,3,3a,4,7,7a-hexahydro-1*H*-isoindole as a clear, colorless oil (19.45 g, 44%): ¹H NMR (500 MHz, CDCl₃) δ 5.29 (s, 2H), 3.88 (bs, 1H), 3.26 (m, 2H), 2.82 (m, 2H), 2.41–2.19 (m, 4H), 1.96 (m, 2H).

Step B: To a 0 °C cooled solution of (3a*R*, 7a*S*)-2,3,3a,4,7,7a-hexahydro-1*H*-isoindole (11.5 g, 93.5 mmol) in CH₂O₂ (200 mL) was added Boc₂O (24.5 g, 112 mmol) and the mixture stirred at rt for 16 h. The mixture was washed with H₂O (100 mL), brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (0–30% EtOAc in hexanes) to give (3a*R*, 7a*S*)-*tert*-butyl 3a, 4,7,7a-tetrahydro-1*H*-isoindole-2(3*H*)-carboxylate (**25**) as a an oil (20.10 g, 49%): ¹H NMR (500 MHz, CDCl₃) δ 5.64 (s, 2H), 3.39 (m, 2H), 3.20 (m, 2H), 3.15 (m, 2H), 2.23–2.19 (m, 4H), 1.97 (m, 2H), 1.57 (s, 9H).

Step C: To a 0 °C cooled mixture of (3a*R*, 7a*S*)-*tert*-butyl 3a,4,7,7a-tetrahydro-1*H*-isoindole-2(3*H*)-carboxylate (**25**, 66.78 g, 224 mmol) in CH₃CN (600 mL), CCl₄ (400 mL), and H₂O (800 mL) was added NaIO₄ (192.3 g, 899 mmol) followed by RuO₂·H₂O (1.19 g, 8.94 mmol). The mixture was stirred at rt for 24 h with mechanical stirring and then filtered through celite. The filter cake was washed with 10% CH₃OH in CH₂Cl₂ (200 mL), and the biphasic mother liquor was separated. The aqueous phase was further extracted with CH₂Cl₂ (3 × 150 mL), and the combined organic extracts were washed with H₂O (100 mL), brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was filtered through a plug of silica gel using a CH₃OH/CH₂Cl₂ eluent system (2–10% CH₃OH in CH₂O₂). The filtrate was concentrated under reduced pressure to give 2,2'-((3*S*,4*R*)-1-(*tert*-butoxycarbonyl)-pyrrolidine-3,4-diyl)diacetic acid (**26**) as a solid (46.75 g, 72%): ¹H NMR (500 MHz, DMSO-*d*₆) δ 12.2 (s, 2H), 3.38 (m, 2H), 3.02 (m, 2H), 2.49 (m, 2H), 2.32 (m⁶, 2H), 2.29 (m, 2H), 1.42 (s, 9H).

Step D: To a suspension of 2,2'-((3*S*,4*R*)-1-(*tert*-butoxycarbonyl)-pyrrolidine-3,4-diyl)diacetic acid (**26**, 6.97 g, 24.31 mmol) in Ac₂O (50 mL) was added NaOAc (1.99 g, 24.31 mmol), and the mixture was heated at 120 °C for 3 h. The mixture was cooled to rt and filtered through celite. The filter cake was washed with Et₂O (5 × 50 mL), and the mother liquor was concentrated under reduced pressure. The resulting residue was purified by flash column chromatography (0–30% EtOAc in hexanes) to give (3a*R*, 6a*S*)-*tert*-butyl 5-oxohexahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate (**27**) as a white foam (2.17 g, 40%): ¹H NMR (500 MHz, CDCl₃) δ 3.69 (m, 2H), 3.22 (m, 2H), 2.91 (m, 2H), 2.50 (m, 2H), 2.17(m, 2H), 1.416 (s, 9H).

Step E: To a –78 °C cooled solution of (3a*R*, 6a*S*)-*tert*-butyl 5-oxohexahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate (**27**, 22.35 g, 99.2 mmol) in THF

(500 mL) was slowly added a solution of LiHMDS in THF (1.0 M, 129 mL). The mixture continued to be stirred at -78°C for 30 min; then, a solution of 1,1,1-trifluoro-*N*-phenyl-*N*-((trifluoromethyl)sulfonyl)methanesulfonamide (49.65 g, 139 mmol) in THF (150 mL) was slowly added. The mixture was stirred for an additional 1 h at -78°C and was then allowed to be stirred at rt for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by flash column chromatography (0–50% EtOAc in hexanes) to give ($\pm$)-(3a*S*,6a*S*)-*tert*-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,3a,6,6a-tetrahydrocyclopenta[*c*]-pyrrole-2(1*H*)-carboxylate (($\pm$)-28) as a clear, viscous oil (1.56 g, quantitative): ^1H NMR (500 MHz, CDCl_3) δ 5.58 (s, 1H), 3.62 (m, 1H), 3.53 (m, 1H), 3.46 (m, 2H), 3.19 (m, 1H), 2.95 (m, 2H), 2.46 (m, 1H), 1.47 (s, 9H).

Step F: To an N_2 degassed mixture of ($\pm$)-(3a*S*,6a*S*)-*tert*-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,3a,6,6a-tetrahydrocyclopenta[*c*]-pyrrole-2(1*H*)-carboxylate (($\pm$)-28, 14.79 g, 41.4 mmol), 2-trifluoromethylphenylboronic acid (19.70 g, 104 mmol), and a 2 M aqueous solution of Na_2CO_3 (250 mL) in DME (500 mL) was added $\text{Pd}(\text{PPh}_3)_4$ (4.80 g, 4.16 mmol). The mixture was heated at 80°C for 6 h, then cooled to rt and diluted with H_2O (500 mL). The aqueous mixture was extracted with EtOAc (2×200 mL), and the combined organic extracts were washed with H_2O (200 mL), brine (200 mL), dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (0–10% EtOAc in hexanes) to give ($\pm$)-(3a*R*,6a*S*)-*tert*-butyl 5-(2-(trifluoromethyl)phenyl)-3,3a,6,6a-tetrahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate (($\pm$)-29) as a clear, viscous oil (13.70 g, 94%): ^1H NMR (500 MHz, CDCl_3) δ 7.65 (m, 1H), 7.47 (m, 2H), 7.25 (m, 1H), 5.58 (s, 1H), 3.85–3.42 (m, 4H), 3.23 (m, 1H), 2.98 (m, 2H), (m, 1H), 1.47 (s, 9H).

Step G: A mixture of ($\pm$)-(3a*R*,6a*S*)-*tert*-butyl 5-(2-(trifluoromethyl)phenyl)-3,3a,6,6a-tetrahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate (($\pm$)-29, 8.63 g, 24.41 mmol) and 10% Pd/C (1.57 g, wet, 10% w/w) in CH_3OH (50 mL) was subjected to an atmosphere of H_2 gas (40 psi) using a Parr Shaker apparatus at rt for 16 h. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by flash column chromatography (0–30% EtOAc in hexanes) to give (3a*R*,5*r*,6a*S*)-*tert*-butyl 5-(2-(trifluoromethyl)phenyl)-hexahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate (**30**) as a clear, viscous oil (0.910 g, 85%): ^1H NMR (500 MHz, CDCl_3) δ 7.69 (m, 1H), 7.51 (m, 2H), 7.25 (m, 1H), 3.49 (m, 5H), 2.75 (m, 2H), 2.92 (m, 2H), 1.52 (m, 2H), 1.48 (s, 9H).

Step H: To a 0°C cooled solution of (3a*R*,5*r*,6a*S*)-*tert*-butyl 5-(2-(trifluoromethyl)phenyl)hexahydrocyclopenta[*c*]pyrrole-2(1*H*)-carboxylate (**30**, 7.94 g, 22.32 mmol) in CH_2Cl_2 (60 mL) was added a 2 M HCl solution in Et_2O (60 mL), and the mixture was allowed to be stirred at rt for 24 h. The mixture was diluted with Et_2O (200 mL), and the precipitated product was filtered to give (3a*R*,5*r*,6a*S*)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole hydrochloride (**31**) as a white solid (5.90 g, 91%): ^1H NMR (500 MHz, CDCl_3) δ 10.17 (bs, 1H), 8.06 (m, 1H), 7.59 (m, 1H), 7.53 (m, 1H), (m, 1H), 3.42 (m, 2H), 3.38 (m, 3H), 3.01 (m, 2H), 2.36 (m, 2H), 1.96 (m, 2H); MS (ESI+) m/z 256 [$m + \text{H}$] $^+$.

(6-Fluoro-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-

(trifluoromethyl)phenyl)piperidin-1-yl)methanone (34).—Step A: A solution of 5-fluoro-2-hydrazinylpyridine (0.460 g, 3.62 mmol) and ethyl 2-oxoacetate (50% in toluene, 0.739 g, 3.62 mmol) in CH₃OH (20 mL) was heated at 60 °C for 1 h. The mixture was then allowed to cool to rt and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (20 mL) and PhI(OAc)₂ (1.28 g, 3.98 mmol) was added. The resulting mixture stirred for 1 h and was subsequently concentrated under reduced pressure. The residue was chromatographed over silica gel (0–80% EtOAc in hexanes) to give ethyl 6-fluoro-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxylate as an off-white solid (0.331 g, 43%): ¹H NMR (300 MHz, CDCl₃) δ 9.18 (m, 1H), 8.00–7.95 (m, 1H), 7.49–7.42 (m, 1H), 4.60 (q, *J* = 7.1 Hz, 2H), 1.52 (t, *J* = 7.1 Hz, 3H); MS (ESI+) *m/z* 210 [M + H]⁺.

Step B: To a solution of ethyl 6-fluoro-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxylate (0.100 g, 0.478 mmol) in THF (5 mL) was added a solution of LiOH·H₂O (0.040 g, 0.956 mmol) in H₂O (2 mL). The mixture was stirred for 20 min and was then acidified to pH 6 with 2 N aqueous HCl followed by subsequent concentration under reduced pressure. The resulting residue (**33a**) was added to a mixture of 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (**10**, 0.127 g, 0.478 mmol), HBTU (0.423 g, 0.956 mmol), and *i*-Pr₂NEt (0.185 g, 1.43 mmol) in DMF (4 mL). The mixture stirred at rt for 16 h and was then poured into H₂O and extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with brine (2 × 30 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) and freeze-dried to give (6-fluoro-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (**34**) as a white solid (0.101 g, 53%): mp 168–170 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.18 (s, 1H), 7.88 (m, 1H), 7.66 (d, *J* = 7.5 Hz, 1H), 7.55–7.30 (m, 4H), 5.76 (m, 1H), 4.99 (m, 1H), 3.40–3.30 (m, 2H), 2.98 (m, 1H), 2.03–1.76 (m, 4H); MS (ESI+) *m/z* 393 [M + h]⁺; HPLC 97.8% purity (AUC), *t*_R = 19.3 min (method B).

(6-Chloro-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-

(trifluoromethyl)phenyl)piperidin-1-yl)methanone (35).—Compound **35** was prepared according to a similar procedure described for the synthesis of **34**. mp 158–160 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.27 (m, 1H), 7.84 (m, 1H), 7.66 (d, *J* = 7.8 Hz, 1H), 7.55–7.30 (m, 4H), 5.73–5.68 (m, 1H), 5.00–4.94 (m, 1H), 3.39–3.28 (m, 2H), 2.93 (m, 1H), 2.04–1.76 (m, 4H); MS (ESI+) *m/z* 408.9, 410.8, 412.0 [M + H]⁺; HPLC 97.0% purity (AUC), *t*_R = 11.5 min (method A).

(6-Methoxy-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-

(Trifluoromethyl)phenyl)piperidin-1-yl)methanone (36).—Compound **36** was prepared according to a similar procedure described for the synthesis of **34**. mp 152–154 °C; ¹H NMR (300 MHz, CDCl₃) δ (d, *J* = 1.8 Hz, 1H), 7.76 (dd, *J* = 9.9, 1.0 Hz, 1H), 7.65 (d, *J* = 7.7 Hz, 1H), 7.55–7.44 (m, 2H), 7.32 (t, *J* = 7.8 Hz, 1H), 7.22 (dd, *J* = 9.9, 2.4 Hz, 1H), 5.76 (m, 1H), 4.97 (m, 1H), 3.90 (s, 3H), 3.39–(m, 2h), 2.98 (m, 1H), 2.03–1.77 (m, 4H); MS (ESI+) *m/z* 405 [M + h]⁺; HPLC 99.4% purity (AUC), *t*_R = 16.4 min (method A).

(6-Ethoxy-[1,2,4]triazolo[4,3-a]pyridin-3-yl)(4-(2-(Trifluoromethyl)phenyl)piperidin-1-yl)methanone (37).—Compound **37** was prepared according to a similar procedure described for the synthesis of **34**. mp 113–115 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.68 (d, *J* = 1.8 Hz, 1H), 7.76 (m, 1H), 7.65 (d, *J* = 7.8 Hz, 1H), 7.54–7.44 (m, 2H), 7.34–7.19 (m, 2H), 5.78–5.73 (m, 1H), 4.96 (m, 1H), 4.12–4.04 (m, 2H), 3.37–2.29 (m, 2H), 3.01–2.92 (m, 1H), 2.03–1.76 (m, 4H), 1.48 (t, *J* = 7.2 Hz, 3H); MS (ESI+) *m/z* 419 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 11.3 min (method A).

(6-(Trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)(4-(2-(Trifluoromethyl)phenyl)piperidin-1-yl)methanone (38).—Compound **38** was prepared according to a similar procedure described for the synthesis of **34**. mp 144–146 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.60 (m, 1H), 8.00 (d, *J* = 9.6 Hz, 1H), 7.66 (d, *J* = 7.8 Hz, 1H), 7.59–7.43 (m, 3H), 7.33 (t, *J* = 7.5 Hz, 1H), 5.73–5.68 (m, 1H), 5.01–4.96 (m, 1H), 3.41–3.32 (m, 2H), 3.05–2.96 (m, 1H), 2.06–1.78 (m, 4H); MS (ESI+) *m/z* 443 [M + H]⁺; HPLC 99.4% purity (AUC), *t_R* = 11.3 min (method A).

(6-Fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)((3*a*R,5*R*,6*a*S)-5-(2-(trifluoromethyl)phenyl)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-methanone (39).—To a solution of ethyl 6-fluoro-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxylate (0.050 g, 0.239 mmol) in THF (4 mL) was added a solution of LiOH·H₂O (0.030 g, 0.717 mmol) in H₂O (3 mL). The mixture was stirred for 20 min, acidified with 2 N aqueous HCl to pH 6, and concentrated under reduced pressure. To a mixture of the resulting crude residue (**33a**) in DMF (4 mL) were added (3*a*R,5*R*,6*a*S)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole hydrochloride (**31**, 0.070 g, 0.239 mmol), HBTU (0.211 g, 0.478 mmol), and *i*-Pr₂NEt (0.093 g, 0.717 mmol). The mixture was stirred at rt for 16 h and then poured into H₂O (30 mL). The mixture was extracted with EtOAc (3 × 30 mL), and the combined organic extracts were washed with brine (3 × 30 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) and freeze-dried to give (6-fluoro-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)((3*a*R,5*R*,6*a*S)-5-(2-(trifluoromethyl)phenyl)-hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)methanone (**39**) as a white solid (0.073 g, 73%): mp 139–141 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.43 (m, 1H), 7.92–7.87 (m, 1H), 7.62 (d, *J* = 8.1 Hz, 1H), 7.54–7.47 (m, 2H), 7.43–7.36 (m, 1H), 7.28 (m, 1H), 4.53–4.41 (m, 2H), 4.0–3.85 (m, 2H), 3.63–3.53 (m, 2H), 2.47–2.36 (m, 2H), 1.73–1.60 (m, 2H); MS (ESI+) *m/z* 419 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 18.0 min (method A).

(6-Chloro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)((3*a*R,5*R*,6*a*S)-5-(2-(trifluoromethyl)phenyl)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-methanone (40).—Compound **40** was prepared according to a similar procedure described for the synthesis of **39**. mp 147–150 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.54 (m, 1H), 7.84 (m, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.53–7.48 (m, 2H), 7.41 (dd, *J* = 10.0, 2.0 Hz, 1H), 7.28 (t, *J* = 8.0 Hz, 1H), 4.50–4.41 (m, 2H), 3.99–3.86 (m, 2H), 3.63–3.55 (m, 1H), 3.04–2.87 (m, 2H), 2.44–2.37 (m, 2H), 1.70–1.62 (m, 2H); MS (ESI+) *m/z* 434.9, 436.4, 437.3 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 12.1 min (method A).

(6-Methoxy-[1,2,4]triazolo[4,3-a]pyridin-3-yl)((3aR,5R,6aS)-5-(2-(Trifluoromethyl)phenyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-methanone (41).—Compound **41** was prepared according to a similar procedure described for the synthesis of **39**. mp 147–152 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.00 (m, 1H), 7.78 (dd, *J* = 9.9, 0.6 Hz, 1H), 7.63–7.47 (m, 3H), 7.30–7.21 (3H), 4.54–4.42 (m, 2H), 3.85 (m, 5H), 3.66–3.53 (m, 1H), 3.04–2.87 (m, 2H), 2.46 (m, 2H), 1.74–1.61 (m, 2H); MS (ESI+) *m/z* 431 [M + H]⁺; HPLC 99.8% purity (AUC), *t_R* = 14.5 min (method A).

(6-Ethoxy-[1,2,4]triazolo[4,3-a]pyridin-3-yl)((3aR,5R,6aS)-5-(2-(Trifluoromethyl)phenyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-methanone (42).—Compound **42** was prepared according to a similar procedure described for the synthesis of **39**. mp 110–112 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.98 (d, *J* = 1.5 Hz, 1H), 7.77 (m, 1H), (d, *J* = 7.8 Hz, 1H), 7.54–7.47 (m, 2H), 7.30–7.23 (m, 2H), 4.42 (m, 2H), 4.10 (q, *J* = 6.9 Hz, 2H), 3.99–3.84 (m, 2H), 3.65–3.52 (m, 1H), 3.06–2.84 (m, 2H), 2.46–2.35 (m, 2H), 1.74–1.60 (m, 2H), 1.48 (t, *J* = 6.9 Hz, 3H); MS (ESI+) *m/z* 445 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 12.0 min (method A).

(6-(Trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-((3aR,5R,6aS)-5-(2-(Trifluoromethyl)phenyl)hexahydrocyclopenta-[c]pyrrol-2(1H)-yl)methanone (43).—Compound **43** was prepared according to a similar procedure described for the synthesis of **39**. mp 154–156 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.88 (m, 1H), 8.00 (d, *J* = 9.6 Hz, 1H), 7.63–7.49 (m, 4H), 7.27 (m, 1H), 4.53–4.41 (m, 2H), 4.02–3.86 (m, 2H), 3.65–3.50 (m, 1H), 3.06–2.89 (m, 2H), 2.36 (m, 2H), 1.72–1.61 (m, 2H); MS (ESI+) *m/z* 469 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 12.6 min (method A).

3-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carbonyl)-[1,2,4]-triazolo[4,3-a]pyridine-6-carbonitriie (48).—Step A: To a solution of ethyl 6-bromo-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxylate (0.365 g, 1.35 mmol) in THF (15 mL) was added a solution of LiOH₂O (0.057 g, 1.35 mmol) in water (5 mL). The mixture was stirred for 20 min, acidified with aqueous 2 N HCl to pH 6, and concentrated under reduced pressure. To a mixture of the resulting crude residue (**44**) in DMF (10 mL) was added 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (**10**, 0.359 g, 1.35 mmol), HBTU (898 g, 2.03 mmol), and *i*-PrNEt (0.523 g, 4.05 mmol). The mixture was stirred at rt for 16 h, diluted with H₂O (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (3 × 60 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–60% EtOAc in hexanes) to give (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (**45**) as a white solid (0.516 g, 84%): ¹H NMR (300 MHz, CDCl₃) δ 9.38 (m, 1H), 7.78 (dd, *J* = 9.6, 0.8 Hz, 1H), 7.66 (d, *J* = 7.8 Hz, 1³H), 7.55–7.44 (m, 3H), 7.32 (t, *J* = 7.7 Hz, 1H), 5.72–5.67 (m, 1H), 5.00–4.94 (m, 1H), 3.39–3.30 (m, 2H), 3.03–2.93 (m, 1H), 2.01–1.81 (m, 4H); MS (ESI+) *m/z* 453 (M + H).

Step B: A mixture of **45** (0.080 g, 0.176 mmol), Zn(CN)₂ (0.041 g, 0.352 mmol), Pd(PPh₃)₄ (0.020 g, 0.0176 mmol), and DMF (1 mL) was heated under microwave irradiation at 130 °C for 30 min. After cooling to rt, the mixture was diluted with CH₂Cl₂ (30 mL), washed with

brine (20 × 30 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–40% EtOAc in hexanes) to give 3-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (**48**) as a white solid (0.063 g, 87%): ¹H NMR (300 MHz, CDCl₃) δ 9.72 (m, 1H), 7.97 (dd, *J* = 9.5, 1.0 Hz, 1H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.55–7.42 (m, 3H), 7.33 (t, *J* = 7.6 Hz, 1H), 5.74–5.69 (m, 1H), 5.00–4.95 (m, 1H), 3.42–3.33 (m, 2H), 3.5–2.95 (m, 1H), 2.06–1.81 (m, 4H); MS (ESI+) *m/z* 400 [M + H]⁺; HPLC >99% purity (AUC), *t_R* = 13.9 min (method A).

(6-Methyl-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2

(trifluoromethyl)phenyl)piperidin-1-yl)methanone (49).—To a mixture of **45** (0.064 g, 0.141 mmol), Fe(acac)₃ (0.005 g, 0.0141 mmol), NMP (0.05 mmol), and THF (1 mL) was added CH₃MgBr (1.4 M solution in THF/toluene, 0.15 mL, 0.212 mmol) dropwise at 0 °C. The resulting mixture was allowed to warm to rt and stirred for 1 h. Two molar aqueous HCl (0.5 mL) was then added, and the mixture was poured into saturated aqueous NaHCO₃ (10 mL). The aqueous mixture was extracted with EtOAc (3 × 10 mL), and the combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–70% EtOAc in hexanes) and freeze-dried to give (6-methyl-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (**49**) as a white solid (0.044 g, 80%): mp 145–147 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.92 (m, 1H), 7.78 (m, 1H), 7.66 (d, *J* = 7.8 Hz, 1H), 7.55–7.44 (m, 2H), 7.34–7.26 (m, 2H), 5.70–5.65 (m, 1H), 4.98 (m, 1H), 3.38–3.28 (m, 2H), 3.02–2.92 (m, 1H), 2.39 (s, 3H), 2.07–1.67 (m, 4H); MS (ESI+) *m/z* 389 [M + H]⁺; HPLC 98.6% purity (AUC), *t_R* = 14.1 min (method A).

3-((3*aR*,5*R*,6*aS*)-5-(2-(Trifluoromethyl)phenyl)-octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (51).—Step A: To a solution of ethyl 6-bromo-[1,2,4] triazolo[4,3-

a]pyridine-3-carboxylate (0.485 g, 1.80 mmol) in THF (15 mL) was added a solution of LiOH₂O (0.076 g, 1.80 mmol) in H₂O (5 mL). The mixture was stirred for 20 min, acidified with 2 N HCl to pH 6, and concentrated under reduced pressure. To the residue were added **31** (0.525 g, 1.80 mmol), HBTU (1.20 g, 2.7 mmol), *i*-Pr₂NEt (0.698 g, 5.40 mmol), and DMF (15 mL). The mixture was stirred at rt for 16 h and then poured into H₂O. The mixture was extracted with EtOAc (3 × 50 mL), and the combined organic extracts were washed with brine (2 × 150 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to give (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)methanone (**50**) as a white solid (0.485 g, 56%): ¹H NMR (300 MHz, CDCl₃) δ 9.65 (m, 1H), 7.98 (dd, *J* = 9.6, 0.9 Hz, 1H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.53–7.47 (m, 3H), 7.28 (m, 1H), 4.51–4.39 (m, 2H), 4.00–3.85 (m, 2H), 3.64–3.52 (m, 1H), 3.07–2.84 (m, 2H), 2.5–2.33 (m, 2H), 1.72–1.60 (m, 2H); MS (ESI+) *m/z* 479 [M + H]⁺.

Step B: A mixture of **50** (0.080 g, 0.167 mmol), Zn(CN)₂ (0.039 g, 0.335 mmol), Pd(PPh₃)₄ (0.019 g, 0.0167 mmol), and DMF (2 mL) was heated at 130 °C under microwave irradiation

for 30 min. After cooling to rt, the mixture was diluted with H₂O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (2 × 50 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to give 3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (**51**) as a white solid (0.073 g, 100%): mp 60–65 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.98 (m, 1H), 7.99 (dd, *J* = 9.5, 0.9 Hz, 1H), 7.63 (d, *J* = 7.8 Hz, 1H), 7.53–7.47 (m, 3H), 7.28 (m, 1H), 4.51–4.40 (m, 2H), 4.02–3.86 (m, 2H), 3.66–3.54 (m, 1H), 3.09–2.86 (m, 2H), 2.49–2.37 (m, 2H), 1.71–1.60 (m, 2H); MS (ESI+) *m/z* 426 [M + H]⁺; HPLC 99.5% purity (AUC), *t*_R = 14.1 min (method A).

3-((3*aR*,5*R*,6*aS*)-5-(2-(Trifluoromethyl)phenyl)-octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic Acid (52**).—**Step A: A mixture of **50** (0.080 g, 0.167 mmol), Mo(CO)₆ (0.066 g, 0.251 mmol), Pd(OAc)₂ (0.0037 g, 0.0167 mmol), xantphos (0.014 g, 0.0251 mmol), CH₃OH (0.054 g, 1.67 mmol), Cs₂CO₃ (109 g, 0.334 mmol), and 1,4-dioxane (2 mL) was heated at 80 °C for 2 h in a sealed vessel. The mixture was allowed to cool to rt and then directly chromatographed over silica gel (0–60% EtOAc in hexanes) to give methyl 3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-3,8,8-triazolo[4,3-*a*]pyridine-6-carboxylate as a white solid (0.024 g, 31%): ¹H NMR (300 MHz, CDCl₃) δ 10.21 (s, 1H), 8.00–7.87 (m, 2H), 7.63–7.47 (m, 3H), 7.28 (m³, 1H), 4.52–4.21 (m, 2H), 4.03–3.88 (m, 5H), 3.65–3.53 (m, 1H), 3.06–2.89 (m, 2H), 2.47–2.36 (m, 2H), 1.73–1.61 (m, 2H); MS (ESI+) *m/z* 459 [M + H]⁺.

Step B: To a solution of 3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylate (0.024 g, 0.0523 mmol) in THF (2 mL) was added a solution of LiOH₂O (0.004 g, 0.105 mmol) in H₂O (1 mL). The mixture was stirred for 30 min at rt, acidified to pH 6 with 2 N aqueous HCl, and subsequently purified by C18 reverse phase column chromatography (10–60% CH₃CN in H₂O) to give 3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (**51**) as a white solid (0.020 g, 86%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.51 (s, 1H), 7.98 (d, *J* = 9.3 Hz, 1H), 7.80–7.74 (m, 2H), 7.6(5–7.61 (m, 2H), 7.38 (t, *J* = 7.5 Hz, 1H), 4.29–4.18 (m, 2H), 3.88–3.78 (m, 2H), 3.41 (m, 1H), 2.97–2.82 (m, 2H), 2.32–2.19 (m, 2H), 1.71–1.66 (m, 2H); MS (ESI+) *m/z* 445 [M + H]⁺; HPLC 97.8% purity (AUC), *t*_R = 12.8 min (method A).

1,1-Dimethyl-3-((3*aR*,5*R*,6*aS*)-5-(2 (trifluoromethyl)phenyl)-octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridin-6-yl)urea (53**).—**A mixture of **50** (0.066 g, 0.138 mmol), Pd(OAc)₂ (0.003 g, 0.0138 mmol), xantphos (0.012 g, 0.0207 mmol), N,N-dimethylurea (0.018 g, 0.207 mmol), Cs₂CO₃ (0.067 g, 0.207 mmol), and 1,4-dioxane (2 mL) was heated at 100 °C for 6 h and cooled to rt. The mixture was chromatographed over silica gel (0–10% CH₃OH in CH₂Cl₂) and further purified by C18 reverse phase column chromatography (10–60% CH₃CN in H₂O) to give 1,1-dimethyl-3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)-

octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]-pyridin-6-yl)urea (**53**) as a white solid (0.023 g, 34%): mp 110–115 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.43 (m, 1H), 7.79 (m, 1H), 7.69–7.47 (m, 4H), 7.30–7.25 (m, 1H), 4.48–4.37 (m, 2H), 3.97–3.83 (m, 2H), 3.63–3.51 (m, 1H), 3.06 (s, 6H), 3.02–2.83 (m, 2H), 2.45–2.34 (m, 2H), 1.72–1.59 (m, 2H); MS (ESI+) *m/z* 487 [M + H]⁺; HPLC 99.7% purity (AUC), *t_R* = 12.2 min (method A).

N-Methyl-3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)-octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]-pyridine-6-sulfonamide (54**).**—Step A: A mixture of 50 (0.090 g, 0.188 mmol), Pd(OAc)₂ (0.0042 g, 0.0188 mmol), xantphos (0.016 g, 0.0282 mmol), benzyl thiol (0.035 g, 0.282 mmol), *i*-Pr₂NEt (0.073 g, 0.564 mmol), and 1,4-dioxane (2 mL) was heated at 110 °C for 16 h. The mixture was allowed to cool to rt, then directly chromatographed over silica gel (0–50% EtOAc in hexanes) to give (6-(benzylthio)-[1,2,4] triazolo[4,3-*a*]pyridin-3-yl)((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-methanone as a mixture with unreacted benzyl mercaptan (0.090 g in a ratio of 1:1.4), a thick oil; MS (ESI+) *m/z* 523 [M + H]⁺.

Step B: Crude (6-(benzylthio)-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-methanone was dissolved in HOAc (3 mL) and H₂O (1 mL). *N*-Chlorosuccinimide (NCS, 0.040 g, 0.296 mmol) was added and the mixture stirred for 3 h at rt, then concentrated under reduced pressure. The residue was partitioned between saturated aqueous Na₂CO₃ (50 mL) and CH₂Cl₂ (50 mL). The organic layer was separated and washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to give 3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)-octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]-pyridine-6-sulfonyl chloride as a mixture with unreacted NCS (0.032 g), a thick oil; ¹H NMR (300 MHz, CDQ3) δ 10.28 (m, 1H), 8.08 (dd, *J* = 9.7, 0.8 Hz, 1H), 7.89 (dd, *J* = 9.7, 1.9 Hz, 1H), 7.62 (d, *J* = 7.8 Hz, 1H), 7.53–7.47 (m, 2H), 7.29 (m, 1H), 4.51–4.40 (m, 2H), 4.3–3.87 (m, 2H), 3.66–3.53 (m, 1H), 3.10–2.86 (m, 2H), 2.49–2.37 (m, 2H), 1.72–1.60 (m, 2H); MS (ESI+) *m/z* 499 [M + H]⁺.

Step C: Crude 3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)-octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4]triazolo[4,3-*a*]-pyridine-6-sulfonyl chloride was dissolved in CH₂Cl₂ (1 mL) and cooled to 0 °C. A mixture of *N*-methylamine (33% in EtOH, 0.018 g, 0.192 mmol) and *i*-Pr₂NEt (0.025 g, 0.192 mmol) in CH₂O₂ (1 mL) was added. The mixture was stirred at rt for 2 h and then concentrated under reduced pressure. The residue was chromatographed by C18 reverse phase column chromatography (10–50% CH₃CN in H₂O) to give *N*-methyl-3-((3*aR*,5*R*,6*aS*)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[*c*]pyrrole-2-carbonyl)-[1,2,4] triazolo[4,3-*a*]pyridine-6-sulfonamide (**54**) as a white solid (6.0 mg, 6% over three steps): mp 148–152 °C; ¹H NMR (300 MHz, CDCl₃) δ 10.0 (m, 1H), 7.99 (dd, *J* = 9.6, 0.8 Hz, 1H), 7.73 (dd, *J* = 9.6, 1.7 Hz, 1H), 7.62 (d, *J* = 7.2 Hz, 1H), 7.54–7.47 (m, 2H), 7.28 (m, 1H), 4.59 (q, *J* = 5.2 Hz, 1H), 4.50–4.39 (m, 2H), 4.01–3.86 (m, 2H), 3.65–3.53 (m, 1H), 3.08–2.86 (m, 2H), 2.81 (d, *J* = 5.3 Hz, 3h), 2.48–2.36 (m, 2H), 1.71–1.60 (m, 2H); MS (ESI+) *m/z* 494 [M + H]⁺; HPLC 99.5% purity (AUC), *t_R* = 13.5 min (method A).

3-(4-(3-Fluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-

[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile (59).—Step A: A solution of *tert*-butyl 4-oxopiperidine-1-carboxylate (**55**, 1.0 g, 5.02 mmol) in THF (30 mL) was cooled to -78°C . LiHMDS (1.0 M solution in THF, 6.52 mL, 6.52 mmol) was added dropwise over 30 min. The mixture was stirred at -78°C for 1 h; then, a solution of 1,1,1-trifluoro-*N*-phenyl-*N*-((trifluoromethyl)sulfonyl)methanesulfonamide (2.52 g, 7.05 mmol) in THF (5.0 mL) was added dropwise over 30 min. The mixture was stirred at 0°C for 3 h and then concentrated under reduced pressure. The residue was chromatographed over silica gel (0–100% EtOAc in hexanes) to provide *tert*-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2*H*)-carboxylate (**56**) as a light-yellow viscous oil (1.50 g, 90%): ^1H NMR (300 MHz, CDCl_3) δ 5.75 (br s, 1H), 4.05–4.02 (m, 2H), 3.64–3.60 (m, 2H), 2.44–2.42 (m, 2H), 1.46 (s, 9H).

Step B: A mixture of *tert*-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2*H*)-carboxylate (**56**, 3.50 g, 10.6 mmol), 3-fluoro-2-(trifluoromethyl)phenylboronic acid (2.19 g, 10.6 mmol), $\text{Pd}(\text{PPh}_3)_4$ (1.22 g, 1.06 mmol), and 2.0 M aqueous Na_2CO_3 solution (65 mL) in DME (120 mL) was heated at 80°C for 6 h. The mixture was allowed to cool to rt and was diluted with 5% aqueous LiCl solution (100 mL). The aqueous mixture was extracted with EtOAc (3×50 mL), and the combined organic extracts were washed with brine (2×50 mL) and concentrated under reduced pressure. The residue was diluted with CH_2O_2 (100 mL) and filtered through a 300 mL silica gel plug, eluting with 10% EtOAc in hexanes (800 mL). The resulting filtrate was concentrated under reduced pressure and chromatographed over silica gel (0–50% EtOAc in hexanes) to provide *tert*-butyl 4-(3-fluoro-2-(trifluoromethyl)phenyl)-3,6-dihydropyridine-1(2*H*)-carboxylate (**57**) as a light-yellow oil (2.39 g, 69%): ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.75–7.61 (m, 1H), 7.49–7.36 (m, 1H), 7.17 (d, $J = 7.8$ Hz, 1H), 5.63–5.54 (m, 1H), 3.97–3.86 (m, 2H), 3.57–3.45 (m, 2H), 2.31–2.18 (m, 2H), 1.42 (s, 9H).

Step C: A mixture of *tert*-butyl 4-(3-fluoro-2-(trifluoromethyl)-phenyl)-3,6-dihydropyridine-1(2*H*)-carboxylate (**57**, 4.7 g, 13.6 mmol) and 10% Pd/C (1.0 g) in EtOH (100 mL) was placed under an atmosphere of H_2 (30 psi) at rt for 18 h. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give *tert*-butyl 4-(3-fluoro-2-(trifluoromethyl)-phenyl)piperidine-1-carboxylate as a clear oil (4.80 g, quantitative): ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.72–7.60 (m, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.30 (dd, $J = 12.3, 8.1$ Hz, 1H), 4.18–4.00 (m, 2H), 3.11–2.95 (m, 1H), 2.92–2.64 (m, 2H), 1.76–1.51 (m, 4H), 1.42 (s, 9H).

Step D: To a solution of *tert*-butyl 4-(3-fluoro-2-(trifluoromethyl)-phenyl)piperidine-1-carboxylate (4.70 g, 13.6 mmol) in CH_2Cl_2 (40 mL) was added 2.0 M HCl in Et_2O (40 mL). The mixture was stirred at rt for 18 h and diluted with Et_2O (100 mL). A precipitate was formed, which was collected by filtration to give 4-(3-fluoro-2-(trifluoromethyl)phenyl)piperidine hydrochloride (**58**) as a white powder (3.69 g, 96%): ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.09–8.80 (m, 2H), 7.83–7.70 (m, 1H), 7.44–7.29 (m, 2H), 3.42–3.31 (m, 2H), 3.29–3.15 (m, 1H), 3.14–2.95 (m, 2H), 2.11–1.91 (m, 2H), 1.89–1.76 (m, 2H); ESI MS $m/z = 248$ $[\text{M} + \text{H}]^+$.

Step E: To a solution of ethyl 6-bromo-[1,2,4] triazolo[4,3-*a*]pyridine-3-carboxylate (0.075 g, 0.28 mmol) in THF (2.5 mL) was added a solution of LiOH·H₂O (0.023 g, 0.56 mmol) in H₂O (1.5 mL). The mixture was stirred for 20 min and was subsequently neutralized with 2 N aqueous HCl. The mixture was concentrated under reduced pressure, and the resulting residue was diluted in DMF (3.0 mL). To this mixture was added 4-(3-fluoro-2-(trifluoromethyl)-phenyl)piperidine hydrochloride (**58**, 0.078 g, 0.28 mmol), HBTU (0.245 g, 0.55 mmol), and *i*-Pr₂NEt (0.11 mL, 0.83 mmol). The resulting mixture was stirred at rt for 16 h. The mixture was subsequently diluted with H₂O (20 mL) and extracted with EtOAc (4 × 30 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to provide (6-bromo-[1,2,4] triazolo [4,3-*a*]pyridin-3-yl)(4-(3-fluoro-2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone as an orange oil (0.087 g, 66%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.13–9.10 (m, 1H), 7.75–7.62 (m 2H), 7.52–7.46 (m, 1H), 7.38–7.25 (m, 1H), 5.30–5.17 (m, 1H), 4.78–4.64 (m, 1H), 3.42–3.28 (m, 3H), 3.11–2.92 (m, 1H), 1.98–1.70 (m, 4H); ESI MS *m/z* = 471 [M + H]⁺.

Step F: A solution of (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(3-fluoro-2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (0.087 g, 0.19 mmol) and Zn(CN)₂ (0.043 g, 0.37 mmol) in DMF (2.0 mL) was sparged with Ar for 10 min. To this solution was then added Pd(PPh₃)₄ (0.021 g, 0.019 mmol), and the vessel was sealed and the mixture was heated to 130 °C via microwave irradiation for 30 min. The mixture was allowed to cool to rt and then diluted with saturated aqueous NaHCO₃ solution (30 mL). The aqueous mixture was extracted with EtOAc (3 × 30 mL), and the combined organic extracts were concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–70% EtOAc in hexanes) to provide 3-(4-(3-fluoro-2-(trifluoromethyl)phenyl)-piperidine-1-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (**59**) as a white solid (0.052 g, 67%): ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.54–9.51 (m, 1H), 8.13 (dd, *J* = 9.5, 1.0 Hz, 1H), 7.81 (dd, *J* = 9.5, 1.5 Hz, 1H), 7.71–7.65 (m, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.32 (dd, *J* = 12.5, 8.5 Hz, 1H), 5.17–5.09 (m, 1H), 4.78–4.70 (m, 1H), 3.44–3.28 (m, 2H), 3.09–3.00 (m, 1H), 1.97–1.75 (m, 4H); ESI MS *m/z* = 418 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 16.7 min (method A).

3-(4-(5-Fluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-

[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (61).—Step A: A mixture of *tert*-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2*H*)-carboxylate (**56**, 1.10 g, 3.32 mmol), 5-fluoro-(2-trifluoromethyl)phenylboronic acid (0.690 g, 3.32 mmol), Pd(PPh₃)₄ (0.384 g, 0.332 mmol), and 2.0 M aqueous Na₂CO₃ solution (20 mL) in DME (50 mL) was heated at 80 °C for 6 h. The mixture was allowed to cool to rt, diluted with EtOAc (50 mL), and filtered through celite to remove solids. The filtrate was washed with brine (4 × 50 mL) and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–80% EtOAc in hexanes) to provide *tert*-butyl 4-(5-fluoro-2-(trifluoromethyl)phenyl)-3,6-dihydropyridine-1(2*H*)-carboxylate as a clear oil (0.542 g, 48%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.80 (dd, *J* = 8.4, 6.0 Hz, 1H), 7.42–7.27 (m, 2H), 5.62 (br s, 1H), 3.97–3.87 (m, 2H), 3.51 (t, *J* = 5.7 Hz, 2H), 2.34–2.23 (m, 2H), 1.42 (s, 9H).

Step B: To a solution of *tert*-butyl 4-(5-fluoro-2-(trifluoromethyl)-phenyl)-3,6-dihydropyridine-1(2*H*)-carboxylate (0.542 g, 1.58 mmol) in CH₂Cl₂ (20 mL) was added 2.0 M HCl in Et₂O (10 mL). The mixture was stirred at rt for 18 h and diluted with Et₂O (30 mL). A precipitate formed, which was collected by filtration to give 4-(5-fluoro-2-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine hydrochloride (**60a**) as a white solid (0.393 g, 88%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.26–9.00 (m, 2H), 7.84 (dd, *J* = 8.7, 5.4 Hz, 1H), 7.46–7.36 (m, 1H), 7.24 (dd, *J* = 9.3, 2.4 Hz, 1H), 5.67 (br s, 1H), 3.76–3.64 (m, 2H), 3.27 (t, *J* = 5.7 Hz), 2.70–2.40 (m, 2H).

Step C: A mixture of 4-(5-fluoro-2-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine hydrochloride (**60a**, 0.393 g, 1.41 mmol) and Pt₂O (0.095 g, 0.42 mmol) in EtOAc (14 mL) was stirred under a balloon of H₂ (1 atm) at rt for 72 h. The mixture was then filtered through celite, and the filtrate was concentrated under reduced pressure. The resulting residue was dissolved in CH₂Cl₂ (4 mL), and 2.0 M HCl in Et₂O (4 mL) was then added. The mixture was stirred at rt for 18 h, and the resulting solids were collected via filtration to provide 4-(5-fluoro-2-(trifluoromethyl)phenyl)piperidine hydrochloride as a white solid (0.309 g, 78%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.81 (br s, 2H), 7.80 (dd, *J* = 9.3, 6.0 Hz, 1H), 7.39–7.26 (m, 2H), 3.43–3.30 (m, 1H), 3.24–2.97 (m, 3H), 2.11–1.90 (m, 2H), 1.88–1.75 (m, 2H); ESI MS *m/z* = 248 [M + H]⁺.

Step D: To a solution of ethyl 6-bromo-[1,2,4] triazolo[4,3-*a*]pyridine-3-carboxylate (0.075 g, 0.28 mmol) in THF (2.5 mL) was added a solution of LiOH·H₂O (0.015 g, 0.35 mmol) in H₂O (1.5 mL). The mixture was stirred for 20 min and was subsequently neutralized with 2 N aqueous HCl. The mixture was concentrated under reduced pressure and the resulting residue was diluted in DMF (3.0 mL). To this mixture was added 4-(5-fluoro-2-(trifluoromethyl)-phenyl)piperidine hydrochloride (0.089 g, 0.32 mmol), HBTU (0.280 g, 0.63 mmol), and *i*-Pr₂NEt (0.17 mL, 0.95 mmol). The resulting mixture was stirred at rt for 16 h. The mixture was subsequently diluted with H₂O (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to provide (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(5-fluoro-2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone as a white solid (0.097 g, 65%): ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.16–9.14 (m, 1H), 7.98 (dd, *J* = 10.0, 1.0 Hz, 1H), 7.77 (dd, *J* = 8.5, 5.5 Hz, 1H), 7.72 (dd, *J* = 9.5, 1.5 Hz, 1H), 7.52 (dd, *J* = 11.0, 3.5 Hz, 1H), 7.29–7.23 (m, 1H), 5.31–5.24 (m, 1H), 4.76–4.70 (m, 1H), 3.42–3.32 (m, 1H), 3.27–3.19 (m, 1H), 3.06–2.96 (m, 1H), 1.98–1.75 (m, 4H).

Step E: A solution of (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(5-fluoro-2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (0.097 g, 0.21 mmol) and Zn(CN)₂ (0.048 g, 0.41 mmol) in DMF (2.5 mL) was purged with Ar for 10 min. To this solution was then added Pd(PPh₃)₄ (0.024 g, 0.021 mmol), and the vessel was sealed, and the mixture was heated to 130 °C via microwave irradiation for 30 min. The mixture was allowed to cool to rt and then diluted with saturated aqueous NaHCO₃ solution (10 mL). The aqueous mixture was extracted with EtOAc (4 × 30 mL), and the combined organic extracts were concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to provide 3-(4-(5-fluoro-2-(trifluoromethyl)phenyl)-

piperidine-1-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (**61**) as a white solid (0.035 g, 41%): ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.54–9.53 (m, 1H), 8.14 (dd, *J* = 9.5, 6.0 Hz, 1H), 7.56 (dd, *J* = 10.5, 2.5 Hz, 1H), 7.78 (dd, *J* = 9.0, 6.0 Hz, 1H), 7.56 (dd, *J* = 10.5, 2.5 Hz, 1H), 7.30–7.24 (m, 1H), 5.20–5.10 (m, 1H), 4.73–4.71 (m, 1H), 3.43–3.34 (m, 1H), 3.29–3.20 (m, 1H), 3.08–3.00 (m, 1H), 1.99–1.77 (m, 4H); ESI MS *m/z* = 418 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 16.8 min (method A).

3-(4-(4-Fluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (62**).**—Compound **62** was prepared according to a similar procedure described for the synthesis of **61**: mp 158–162 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.53 (s, 1H), 8.14 (dd, *J* = 9.0, 0.9 Hz, 1H), 7.82 (dd, *J* = 9.6, 1.5 Hz, 1H), 7.77–7.67 (m, 1H), 7.61–7.67 (m, 2H), 5.19–5.04 (m, 1H), 4.80–4.67 (m, 1H), 3.46–3.14 (m, 2H), 3.12–2.94 (m, 1H), 2.02–1.70 (m, 4H); ESI MS *m/z* = 418 [M + H]⁺; HPLC 98.5% purity (AUC), *t*_R = 10.6 min (method A).

3-(4-(2-Fluoro-6-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (64**).**—Step A: A mixture of *tert*-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2*H*)-carboxylate (**56**, 1.20 g, 3.62 mmol), (2-fluoro-6-(trifluoromethyl)phenyl)boronic acid (0.528 g, 2.53 mmol), Pd-(PPh₃)₄ (0.292 g, 0.253 mmol), and 2.0 M aqueous Na₂CO₃ solution (20 mL) in DME (30 mL) was heated at 80 °C for 6 h. The mixture was allowed to cool to rt, diluted with EtOAc (50 mL), and filtered through celite to remove solids. The filtrate was washed with brine (4 × 50 mL) and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% EtOAc in hexanes) to provide *tert*-butyl 4-(2-fluoro-6-(trifluoromethyl)phenyl)-3,6-dihydropyridine-1(2*H*)-carboxylate as a clear oil (0.479 g, 39%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.66–7.51 (m, 3H), 5.68 (s, 1H), 4.4–3.82 (m, 2H), 3.67–3.39 (m, 2H), 2.39–2.02 (m, 2H), 1.43 (s, 9H).

Step B: A mixture of *tert*-butyl 4-(2-fluoro-6-(trifluoromethyl)-phenyl)-3,6-dihydropyridine-1(2*H*)-carboxylate (0.479 g, 1.41 mmol) and Pt₂O (0.095, 0.42 mmol) in EtOAc (15 mL) and HOAc (82 μL, 1.4 mmol) was stirred at rt under a balloon of H₂ (1 atm) for 72 h. The mixture was diluted with EtOAc (50 mL) and filtered over celite. The filtrate was concentrated under reduced pressure, and the resulting residue was chromatographed over silica gel (0–10% EtOAc in hexanes) to afford *tert*-butyl 4-(2-fluoro-6-(trifluoromethyl)-phenyl)piperidine-1-carboxylate (**63**) as a white solid: ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.62–7.48 (m, 3H), 4.15–3.94 (m, 1H), 3.10–2.94 (m, 2H), 2.93–2.67 (m, 2H), 2.00–1.79 (m, 2H), 1.67–1.55 (m, 2H), 1.42 (s, 9H).

Step C: To a solution of *tert*-butyl 4-(2-fluoro-6-(trifluoromethyl)-phenyl)piperidine-1-carboxylate (**63**, 0.219 g, 0.63 mmol) in CH₂Cl₂ (5 mL) was added 2.0 M HCl in Et₂O (4 mL). The mixture stirred at rt for 18 h and was diluted with Et₂O (50 mL). A precipitate formed, which was collected by filtration to give 4-(2-fluoro-6-(trifluoromethyl)phenyl)piperidine hydrochloride as a white solid (0.158 g, 88%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.82 (br s, 1H), 8.50 (br s, 1H), 7.66–7.48 (m, 3H), 3.24–2.95 (m, 3H), 2.35–2.15 (m, 2H), 1.87–1.74 (m, 2H); ESI MS *m/z* = 248 [M + H]⁺.

Step D: To a solution of ethyl 6-bromo-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxylate (0.072 g, 0.27 mmol) in THF (2.5 mL) was added a solution of LiOH·H₂O (0.012 g, 0.29 mmol) in H₂O (1.5 mL). The mixture was stirred for 20 min and was subsequently neutralized with 2 N aqueous HCl. The mixture was concentrated under reduced pressure, and the resulting residue was diluted in DMF (3.0 mL). To this mixture was added 4-(2-fluoro-6-(trifluoromethyl)-phenyl)piperidine hydrochloride (0.075 g, 0.27 mmol), HBTU (0.236 g, 0.53 mmol), and *i*-Pr₂NEt (0.14 mL, 0.80 mmol). The resulting mixture was stirred at rt for 16 h. The mixture was subsequently diluted with H₂O (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to provide (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-fluoro-6-(trifluoromethyl)phenyl)piperidin-1-yl)methanone as a white solid (0.080 g, 64%): ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.12–9.10 (m, 1H), 8.00–7.95 (m, 1H), 7.74–7.68 (m, 1H), 7.65–7.50 (m, 3H), 5.29–5.15 (m, 1H), 4.82–4.68 (m, 1H), 3.41–3.19 (m, 2H), 3.07–2.97 (m, 1H), 2.34–2.19 (m, 1H), 2.15–2.02 (m, 1H), 1.93–1.75 (m, 2H); ESI MS *m/z* = 472 [M + H]⁺.

Step E: A solution of (6-bromo-[1,2,4]triazolo[4,3-*a*]pyridin-3-yl)(4-(2-fluoro-6-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (0.080 g, 0.17 mmol) and Zn(CN)₂ (0.040 g, 0.34 mmol) in DMF (2.5 mL), was sparged with Ar for 10 min. To this solution was then added Pd(PPh₃)₄ (0.019 g, 0.017 mmol), and the vessel was sealed, and the mixture was heated to 130 °C via microwave irradiation for 30 min. The mixture was allowed to cool to rt and then diluted with saturated aqueous NaHCO₃ solution (10 mL). The aqueous mixture was extracted with EtOAc (4 × 30 mL), and the combined organic extracts were concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to provide 3-(4-(2-fluoro-6-(trifluoromethyl)phenyl)-piperidine-1-carbonyl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carbonitrile (**64**) was a white solid (0.023 g, 33%): ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.54–9.52 (m, 1H), 8.14–8.11 (m, 1H), 7.82–7.78 (m, 1H), 7.64–7.59 (m, 1H), 7.57–7.50 (m, 2H), 5.17–5.10 (m, 1H), 4.79–4.72 (m, 1H), 3.40–3.24 (m, 2H), 3.07–2.98 (m, 1H), 2.30–2.19 (m, 1H), 2.14–2.03 (m, 1H), 1.91–1.79 (m, 2H); ESI MS *m/z* = 418 [M + H]⁺; HPLC >99% purity (AUC), *t*_R = 9.9 min (method A).

(1H-Benzo[d]imidazol-2-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)methanone (65).—A mixture of 4-(2-(trifluoromethyl)-phenyl)piperidine hydrochloride (**10**, 0.128 g, 0.483 mmol), 1H-benzo[d]imidazole-2-carboxylic acid (0.070 g, 0.436 mmol), *i*-Pr₂NEt (0.25 mL, 1.49 mmol), and HBTU (0.274 g, 0.724 mmol) in DMF (5 mL) was stirred at rt for 16 h. The mixture was diluted with H₂O (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with H₂O (3 × 50 mL), brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (10–50% EtOAc in hexanes) to afford (1H-Benzo[d]imidazol-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (**65**) as a white solid (0.121 g, 67%): mp 178–185 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.11 (s, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 7.71–7.60 (m, 3H), 7.55 (d, *J* = 8.5 Hz, 1H), 7.45–7.38 (m, 1H), 7.35–7.29 (m, 1H), 7.28–7.22 (m, 1H), 5.83–5.77 (m, 1H), 4.79–4.73 (m, 1H), 3.35–

3.26(m, 1H), 3.25–3.16 (m, 1H), 3.00–2.90 (m, 1H), 1.95–1.71 (m, 4H); ESI MS m/z 374 [M + H]⁺; HPLC 98.8% purity (AUC), t_R = 13.4 min (method A).

Benzo[d]oxazol-2-yl(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (66).

—Compound **66** was prepared according to a similar procedure described for the synthesis of **65**. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.92–7.86 (m, 2H), 7.71–7.41 (m, 6H), 4.70–4.67 (m, 2H), 3.80–3.35 (m, 1H), 3.23–3.18 (m, 1H), 3.05–2.99 (m, 1H), 1.92–1.77 (m, 4H); ESI MS m/z 375 [M + H]⁺; HPLC 99.4% purity (AUC), t_R = 15.1 min (method A).

Benzo[d]thiazol-2-yl(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (67).

—Compound **67** was prepared according to a similar procedure described for the synthesis of **65**. mp 151–153 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.22–8.13 (m, 2H), 7.71–7.57 (m, 5H), 7.44–7.41 (m, 1H), 5.40–5.37 (m, 1H), 4.71–4.68 (m, 1H), 3.99–3.21 (m, 2H), 3.01–3.03 (m, 1H), 1.92–1.83 (m, 4H); ESI MS m/z 391 [M + H]⁺; HPLC 98.4% purity (AUC), t_R = 16.6 min (method A).

(1H-Indol-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (68).

—Compound **68** was prepared according to a similar procedure described for the synthesis of **65**. mp 189–192 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.56 (s, 1H), 7.71–7.68 (m, 2H), 7.67–7.63 (m, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.45–7.40 (m, 2H), 7.20–7.16 (m, 1H), 7.06–7.02 (m, 1H), 6.82 (dd, J = 2.5, 1.0 Hz, 1H), 4.63 (d, J = 12.5 Hz, 2H), 3.23–2.94 (m, 3H), 1.88–1.75 (m, 4H); ESI MS m/z 373 [M + H]⁺; HPLC 99.9% purity (AUC), t_R = 19.8 min (method C).

(1H-Pyrrolo[2,3-c]pyridin-2-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)-methanone (69).

—Compound **69** was prepared according to a similar procedure described for the synthesis of **65**. mp 214–218 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.99 (s, 1H), 8.90 (s, 1H), 8.22 (d, J = 5.5 Hz, 1H), 7.72–7.68 (m, 2H), 7.67–7.63 (m, 1H), 7.46–7.40 (m, 1H), 7.38 (d, J = 6.0 Hz, 1H), 6.98 (d, J = 1.0 Hz, 1H), 4.73–4.44 (m, 2H), 3.08–2.77 (m, 3H), 1.93–1.74 (m, 4H); ESI MS m/z 374 [M + H]⁺; HPLC 99.8% purity (AUC), t_R = 11.5 min (method A).

(1H-Pyrrolo[3,2-b]pyridin-2-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)-methanone (70).

—Compound **70** was prepared according to a similar procedure described for the synthesis of **65**. mp 275–278 °C decomp.; ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.81 (s, 1H), 8.39 (dd, J = 6.0, 1.5 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.73–7.63 (m, 3H), 7.46–7.41 (m, 1H), 7.19 (dd, J = 8.5, 4.5 Hz, 1H), 6.93 (d, J = 1.5 Hz, 1H), 4.73–4.42 (m, 2H), 3.28–2.81 (m, 3H), 1.92–1.76 (m, 4H); ESI MS m/z 374 [M + H]⁺; HPLC 99.5% purity (AUC), t_R = 13.0 min (method A).

Imidazo[1,2-a]pyridin-2-yl(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)-methanone (71).

—Compound **71** was prepared according to a similar procedure described for the synthesis of **65**. mp 130–133 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.16 (d, J = 7.8 Hz, 1H), 8.09 (s, 1H), 7.62 (m, 2H), 7.53 (m, 2H), 7.48 (m, 1H), 7.30 (m, 1H), 6.82 (m, 1H), 5.42 (m, 1H), 4.91 (m, 1H), 3.26 (m, 2H), 2.98 (m, 1H), 1.83 (m, 4H); MS (ESI+) m/z 374 [M + H]⁺; HPLC 97.6% purity (AUC), t_R = 9.9 min (method A).

Imidazo[1,2-*b*]pyridazin-2-yl(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)methanone (72).—Compound **72** was prepared according to a similar procedure described for the synthesis of **65**. mp 133–135 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.61–8.58 (m, 2H), 8.21–8.18 (m, 1H), 7.70–7.60 (m, 3H), 7.44–7.39 (m, 1H), 7.33–7.29 (m, 1H), 5.15–5.06 (m, 1H), 4.77–4.67 (m, 1H), 3.28–3.12 (m, 2H), 2.93–2.81 (m, 1H), 1.90–1.67 (m, 4H); ESI MS *m/z* 375 [M + H]⁺; HPLC 99.6% purity (AUC), *t*_R = 9.5 min (method A).

(6-Methylimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (74).—Step A: A mixture of 4-(2-(trifluoromethyl)phenyl)piperidine hydrochloride (**10**, 0.996 g, 3.76 mmol), 6-chloroimidazo[1,2-*b*]pyridazine-2-carboxylic acid (0.743 g, 3.76 mmol), *i*-Pr₂N₂Et (1.96 mL, 11.28 mmol), and HBTU (2.13 g, 5.64 mmol) in DMF (80 mL) was stirred at rt for 16 h. The mixture was diluted with H₂O (150 mL) and extracted with EtOAc (3 × 150 mL). The combined organic extracts were washed with H₂O (3 × 100 mL), brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (10–50% EtOAc in hexanes) to afford (6-chloroimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)-piperidin-1-yl)methanone (**73**) as an off-white solid (1.35 g, 87%): ¹H NMR (300 MHz, CDCl₃) δ 8.40 (s, 1H), 7.91 (m, 1H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.52–7.43 (m, 2H), 7.31 (t, *J* = 6.6 Hz, 1H), 7.13 (d, *J* = 9.5 Hz, 1H), 5.30–5.23 (m, 1H), 4.96–4.91 (m, 1H), 3.30–3.24 (m, 2H), 2.90 (m, 1H), 1.96–1.83 (m, 4H); MS (ESI+) *m/z* 409 [M + H]⁺.

Step B: A mixture of (6-chloroimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (**73**, 0.030 g, 0.0734 mmol), trimethylboroxine (0.014 g, 0.110 mmol), 1,1'-bis(diphenylphosphino)ferrocene (0.006 g, 0.00734 mmol), K₂CO₃ (0.020 g, 0.147 mmol), 1,4-dioxane (2 mL), and H₂O (0.3 mL) was heated in sealed tube under an atmosphere of N₂ at 110 °C for 5 h. The mixture was allowed to cool to rt, diluted with EtOAc, and solids filtered. The filtrate was concentrated under reduced pressure, and the residue was chromatographed over silica gel (0–3% CH₃OH in CH₂Cl₂) to give (6-methylimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (**74**) as an off-white solid (0.015 g, 52%): mp 144–147 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.35 (s, 1H), 7.82 (d, *J* = 9.4 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.53–7.44 (m, 2H), 7.30 (m, 1H), 6.96 (d, *J* = 9.4 Hz, 1H), 5.30 (m, 1H), 4.94 (m, 1H), 3.26 (m, 2H), 2.93 (m, 1H), 2.59 (s, 3H), 1.89–1.77 (m, 4H); MS (ESI+) *m/z* 489 [M + H]⁺; HPLC 95.9% purity (AUC), *t*_R = 13.3 min (method A).

(6-Methoxyimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (75).—To a solution of **73** (0.060 g, 0.147 mmol) in CH₃OH (6 mL) was added a solution of NaOCH₃ in CH₃OH (0.5 M, 2.94 mL, 1.47 mmol). The mixture was heated to 70 °C for 1 h, allowed to cool to rt, and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂, and the solution was washed with saturated NaHCO₃, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–70% EtOAc in hexanes) and lyophilized from CH₃CN and H₂O to give (6-methoxyimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (**75**) as a white solid (0.015 g, 25%): mp

120–123 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.24 (s, 1H), 7.76 (d, *J* = 9.6 Hz, 1H), 7.64 (d, *J* = 8.1 Hz, 1H), 7.49 (m, 2H), 7.30 (m, 1H), 6.74 (d, *J* = 9.6 Hz, 1H), 5.38 (m, 1H), 4.93 (m, 1H), 4.00 (s, 3H), 3.25 (m, 2H), 2.88 (m, 1H), 1.89–1.77 (m, 4H); MS (ESI+) *m/z* 405 [M + H]⁺; HPLC 96.6% purity (AUC), *t_R* = 13.9 min (method A).

(6-Cyclopropylimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (76).—A mixture of **73** (0.050 g, 0.122 mmol), potassium cyclopropyltrifluoroborate (0.026 g, 0.183 mmol), Pd(OAc)₂ (0.002 g, 0.0061 mmol), di-(1-admantyl)-*n*-butylphosphine (0.004 g, 0.0122 mmol), and Cs₂CO₃ (0.119 g, 0.366 mmol) in toluene (2 mL) and H₂O (0.2 mL) was heated at 100 °C for 3 h. The mixture was concentrated under reduced pressure, and the resulting residue was chromatographed over silica gel (0–60% EtOAc in hexanes) to give (6-cyclopropylimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)-phenyl)piperidin-1-yl)methanone (**76**) as a white solid (0.035 g, 69%): ¹H NMR (300 MHz, CDCl₃) δ 8.30 (s, 1H), 7.78 (m, 1H), 7.63 (d, *J* = 7.8 Hz, 1H), 7.54–7.44 (m, 2H), 7.30 (t, *J* = 7.8 Hz, 1H), 6.88 (d, *J* = 9.6 Hz, 1H), 5.30 (m, 1H), 4.94 (m, 1H), 3.27 (m, 2H), 2.89 (m, 1H), 2.12–1.81 (m, 5H), 1.14–1.08 (m, 4H); MS (ESI+) *m/z* 415 [M + H]⁺; HPLC 98.2% purity (AUC), *t_R* = 13.7 min (method A).

(6-(Pyrrolidin-1-yl)imidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (77).—A mixture of **73** (0.030 g, 0.0734 mmol) and pyrrolidine (1.5 mL) was heated at 100 °C for 3 h. The mixture cooled to rt and was concentrated under reduced pressure. The residue was chromatographed over silica gel (0–70% EtOAc in hexanes) to give (6-(pyrrolidin-1-yl)imidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)-methanone (**77**) as an off-white solid (0.046 g, 85%): mp 170–171 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.15 (s, 1H), 7.63 (d, *J* = 9.3 Hz, 1H), 7.53–7.44 (m, 2H), 7.30 (t, *J* = 7.8 Hz, 1H), 6.66 (d, *J* = 9.9 Hz, 1H), 5.42 (m, 1H), 4.93 (m, 1H), 3.50 (m, 4h), 3.24 (m, 2H), 2.87 (m, 1H), 2.07–1.80 (m, 8h); MS (ESI+) *m/z* 444 [M + H]⁺; HPLC 99.2% purity (AUC), *t_R* = 12.0 min (method A).

(6-Morpholinoimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methanone (78).—A mixture of **73** (0.030 g, 0.0734 mmol) and morpholine (1.5 mL) was heated at 120 °C for 2 h. The mixture was allowed to cool to rt and was concentrated under reduced pressure. The resulting residue was dissolved in CH₂Cl₂, and the solution was washed with aqueous saturated NaHCO₃ solution, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–100% EtOAc in hexanes) to give (6-morpholinoimidazo[1,2-*b*]pyridazin-2-yl)(4-(2-(trifluoromethyl)-phenyl)piperidin-1-yl)methanone (**78**) as a white solid (0.015 g, 44%): mp 203–205 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.17 (s, 1H), 7.71 (d, *J* = 10.0 Hz, 1H), 7.63 (d, *J* = 7.7 Hz, 1H), 7.53–7.43 (m, 2H), 7.30 (m, 1H), 6.96 (d, *J* = 10.0 Hz, 1H), 5.38 (m, 1H), 4.93 (m, 1H), 3.85 (m, 4H), 3.50 (m, 4H), 3.24 (m, 2H), 2.88 (m, 1H), 1.88–1.76(m, 4H); MS (ESI+) *m/z* 460 [M + H]⁺; HPLC 98.0% purity (AUC), *t_R* = 12.1 min (method A).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This study was supported by NIH Grants U01 NS074476 and R21 EY027027 to K.P. and R01 DK068437 and R01 DK101251 to W.S.B., as well as by unrestricted funds from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, Columbia University. This project has also been funded in whole or in part with Federal funds from the National Institute of Neurological Disorders and Stroke, the National Eye Institute, the NIH Blueprint Neurotherapeutics Network, Blueprint for Neuroscience Research Program, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201100013C.

ABBREVIATIONS

<i>Abca4</i>	ATP-binding cassette, subfamily A (ABC1), member 4
NASH	nonalcoholic steatohepatitis
NAFLD	nonalcoholic fatty liver disease
RBP4	retinol-binding protein 4
TTR	transthyretin
Ar	argon
rt	room temperature
SPA	scintillation proximity assay
HTRF	homogenous time resolved fluorescence assay
HFD	high fat diet
HLM	human liver microsomes
RLM	rat liver microsomes
<i>n</i>-BuLi	<i>n</i> -butyl lithium
THF	tetrahydrofuran

REFERENCES

- (1). Schlehuber S; Skerra A Lipocalins in drug discovery: from natural ligand-binding proteins to “anticalins”. *Drug Discovery Today* 2005, 10, 23–33. [PubMed: 15676296]
- (2). Yang Q; Graham TE; Mody N; Preitner F; Peroni OD; Zabolotny JM; Kotani K; Quadro L; Kahn BB Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 2005, 436, 356–362. [PubMed: 16034410]
- (3). Bobbert T; Raila J; Schwarz F; Mai K; Henze A; Pfeiffer AFH; Schweigert FJ; Spranger J Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. *Atherosclerosis* 2010, 213, 549–551. [PubMed: 20832065]
- (4). Kawaguchi R; Zhong M; Kassai M; Ter-Stepanian M; Sun H Vitamin A transport mechanism of the multitransmembrane cell-surface receptor STRA6. *Membranes* 2015, 5, 425–453. [PubMed: 26343735]

- (5). Alapatt P; Guo FJ; Komanetsky SM; Wang SP; Cai JJ; Sargsyan A; Diaz ER; Bacon BT; Aryal P; Graham TE Liver retinol transporter and receptor for serum retinol-binding protein (RBP4). *J. Biol. Chem.* 2013, 288, 1250–1265. [PubMed: 23105095]
- (6). Tsutsumi C; Okuno M; Tannous L; Piantedosi R; Allan M; Goodman DS; Blaner WS Retinoids and retinoid-binding protein expression in rat adipocytes. *J. Biol. Chem.* 1992, 267, 1805–1810. [PubMed: 1370481]
- (7). Kotnik P; Fischer-Posovszky P; Wabitsch M RBP4: a controversial adipokine. *Eur. J. Endocrinol.* 2011, 165, 703–711. [PubMed: 21835764]
- (8). Graham TE; Yang Q; Bluher M; Hammarstedt A; Ciaraldi TP; Henry RR; Wason CJ; Oberbach A; Jansson PA; Smith U; Kahn BB Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. *N. Engl. J. Med.* 2006, 354, 2552–2563. [PubMed: 16775236]
- (9). Aeberli I; Biebinger R; Lehmann R; L'Allemand D; Spinass GA; Zimmermann MB Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. *J. Clin. Endocrinol. Metab.* 2007, 92, 4359–4365. [PubMed: 17726085]
- (10). Kowalska I; Strazekowski M; Adamska A; Nikolajuk A; Karczewska-Kupczewska M; Oziomek E; Gorska M Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. *J. Clin. Endocrinol. Metab.* 2008, 93, 2786–2789. [PubMed: 18430770]
- (11). Ingelsson E; Sundstrom J; Melhus H; Michaelsson K; Berne C; Vasan RS; Riserus U; Blomhoff R; Lind L; Arnlov J Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. *Atherosclerosis* 2009, 206, 239–244. [PubMed: 19339013]
- (12). Qi Q; Yu Z; Ye X; Zhao F; Huang P; Hu FB; Franco OH; Wang J; Li H; Liu Y; Lin X Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. *J. Clin. Endocrinol. Metab.* 2007, 92, 4827–4834. [PubMed: 17878249]
- (13). Norseen J; Hosooka T; Hammarstedt A; Yore MM; Kant S; Aryal P; Kiernan UA; Phillips DA; Maruyama H; Kraus BJ; Ushuva A; Davis RJ; Smith U; Kahn BB Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. *Mol. Cell. Biol.* 2012, 32, 2010–2019. [PubMed: 22431523]
- (14). Moraes-Vieira PM; Yore MM; Dwyer PM; Syed I; Aryal P; Kahn BB RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. *Cell Metab.* 2014, 19, 512–526. [PubMed: 24606904]
- (15). Farjo KM; Farjo RA; Halsey S; Moiseyev G; Ma JX Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism. *Mol. Cell. Biol.* 2012, 32, 5103–5115. [PubMed: 23071093]
- (16). Berry DC; Jacobs H; Marwarha G; Gely-Pernot A; O'Byrne SM; DeSantis D; Klopstein M; Feret B; Dennefeld C; Blaner WS; Croniger CM; Mark M; Noy N; Ghyselinck NB The STRA6 receptor is essential for retinol-binding protein-induced insulin resistance but not for maintaining vitamin A homeostasis in tissues other than the eye. *J. Biol. Chem.* 2013, 288, 24528–24539. [PubMed: 23839944]
- (17). Berry DC; O'Byrne SM; Vreeland AC; Blaner WS; Noy N Cross talk between signaling and vitamin A transport by the retinol-binding protein receptor STRA6. *Mol. Cell. Biol.* 2012, 32, 3164–3175. [PubMed: 22665496]
- (18). Quadro L; Blaner WS; Hamberger L; Van Gelder RN; Vogel S; Piantedosi R; Gouras P; Colantuoni V; Gottesman ME Muscle expression of human retinol-binding protein (RBP). Suppression of the visual defect of RBP knockout mice. *J. Biol. Chem.* 2002, 277, 30191–30197. [PubMed: 12048218]
- (19). Motani A; Wang Z; Conn M; Siegler K; Zhang Y; Liu Q; Johnstone S; Xu H; Thibault S; Wang Y; Fan P; Connors R; Le H; Xu G; Walker N; Shan B; Coward P Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. *J. Biol. Chem.* 2009, 284, 7673–7680. [PubMed: 19147488]

- (20). Du M; Otalora L; Martin AA; Moiseyev G; Vanlandingham P; Wang QL; Farjo R; Yeganeh A; Quiambao A; Farjo KM Transgenic mice overexpressing serum retinol-binding protein develop progressive retinal degeneration through a retinoid-independent mechanism. *Mol. Cell. Biol.* 2015, 35, 2771–2789. [PubMed: 26055327]
- (21). Fedders R; Muenzner M; Weber P; Sommerfeld M; Knauer M; Kedziora S; Kast N; Heidenreich S; Raila J; Weger S; Henze A; Schupp M Liver-secreted RBP4 does not impair glucose homeostasis in mice. *J. Biol. Chem.* 2018, 293, 15269–15276. [PubMed: 30126844]
- (22). Lee S-A; Yuen JJ; Jiang H; Kahn BB; Blaner WS Adipocyte-specific overexpression of retinol-binding protein 4 causes hepatic steatosis in mice. *Hepatology* 2016, 64, 1534–1546. [PubMed: 27227735]
- (23). Huang H-J; Nanao M; Stout T; Rosen J 2WR6: Structure of the Complex of RBP4 with Linoleic Acid; Protein Data Bank, 2009.
- (24). Nanao MS; Mercer D; Nguyen L; Buckley D; Stout TJ 2WQ9: Crystal Structure of RBP4 bound to Oleic Acid; Protein Data Bank, 2009.
- (25). Perduca M; Nicolis S; Mannucci B; Galliano M; Monaco HL Human plasma retinol-binding protein (RBP4) is also a fatty acid-binding protein. *Biochim. Biophys. Acta, Mol. Cell Biol. Lipids* 2018, 1863, 458–466. [PubMed: 29414511]
- (26). Cioffi CL; Dobri N; Freeman EE; Conlon MP; Chen P; Stafford DG; Schwarz DMC; Golden KC; Zhu L; Kitchen DB; Barnes KD; Raciz B; Qin Q; Michelotti E; Cywin CL; Martin WH; Pearson PG; Johnson G; Petrukhin K Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease. *J. Med. Chem.* 2014, 57, 7731–7757. [PubMed: 25210858]
- (27). Cioffi CL; Raciz B; Freeman EE; Conlon MP; Chen P; Stafford DG; Schwarz DM; Zhu L; Kitchen DB; Barnes KD; Dobri N; Michelotti E; Cywin CL; Martin WH; Pearson PG; Johnson G; Petrukhin K Bicyclic [3.3.0]-octahydrocyclopenta-[c]pyrrolo antagonists of retinol binding protein 4: potential treatment of atrophic age-related macular degeneration and Stargardt disease. *J. Med. Chem.* 2015, 58, 5863–5888. [PubMed: 26181715]
- (28). Raciz B; Varadi A; Kong J; Allikmets R; Pearson PG; Johnson G; Cioffi CL; Petrukhin K A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle. *J. Biol. Chem.* 2018, 293, 11574–11588. [PubMed: 29871924]
- (29). Lassila T; Hokkanen J; Aatsinki SM; Mattila S; Turpeinen M; Tolonen A Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated. *Chem. Res. Toxicol.* 2015, 28, 2292–2303. [PubMed: 26558897]
- (30). Wang Y; Connors R; Fan P; Wang X; Wang Z; Liu J; Kayser F; Medina JC; Johnstone S; Xu H; Thibault S; Walker N; Conn M; Zhang Y; Liu Q; Grillo MP; Motani A; Coward P; Wang Z Structure-assisted discovery of the first non-retinoid ligands for retinol-binding protein 4. *Bioorg. Med. Chem. Lett.* 2014, 24, 2885–2891. [PubMed: 24835984]
- (31). Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)-amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. *J. Med. Chem.* 2005, 48, 1857–1872. [PubMed: 15771431]
- (32). (a)Dart MJ; Searle XB; Tietje KR; Toupence RB Azabicyclic Compounds are Central Nervous System Active Agents. Google Patents PCT Int. Appl. WO2004016604A2, 2004. (b)Lauffer D; Li P; Waal N; McGinty K; Tang Q; Ronkin S; Farmer L; Shannon D; Jacobs D C-Met Protein Kinase Inhibitors. Google Patents PCT Int. Appl. WO2009045992A2, 2009. (c)Guillemont JEG; Lançois DFA; Motte MMS; Koul A; Balemans WMA; Arnoult EPA Antibacterial Cyclopenta[c]pyrrole Substituted 3,4-Dihydro-1h-[1,8]naphthyridinones. Google Patents PCT Int. Appl. WO2013021054A1, 2013.
- (33). Motani A; Wang Z; Conn M; Siegler K; Zhang Y; Liu Q; Johnstone S; Xu H; Thibault S; Wang Y; Fan P; Connors R; Le H; Xu G; Walker N; Shan B; Coward P Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. *J. Biol. Chem.* 2009, 284, 7673–7680. [PubMed: 19147488]

- (34). Dobri N; Qin Q; Kong J; Yamamoto K; Liu Z; Moiseyev G; Ma JX; Allikmets R; Sparrow JR; Petrukhin K A1120, a non-retinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. *Invest. Ophthalmol. Vis. Sci.* 2013, 54, 85–95. [PubMed: 23211825]
- (35). Johnson TW; Gallego RA; Edwards MP Lipophilic efficiency as an important metric in drug design. *J. Med. Chem.* 2018, 61, 6401–6420. [PubMed: 29589935]
- (36). Zimmerlin A; Trunzer M; Faller B CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. *Drug Metab. Dispos.* 2011, 39, 1039–1046. [PubMed: 21383203]
- (37). Silvaroli JA; Widjaja-Adhi MAK; Trischman T; Chelstowska S; Horwitz S; Banerjee S; Kiser PD; Blaner WS; Golczak M Abnormal cannabidiol modulates vitamin A metabolism by acting as a competitive inhibitor of CRBP1. *ACS Chem. Biol.* 2019, 434. [PubMed: 30721022]
- (38). Vogel S; Piantedosi R; O’Byrne SM; Kako Y; Quadro L; Gottesman ME; Goldberg IJ; Blaner WS Retinol-binding protein-deficient mice: biochemical basis for impaired vision. *Biochemistry* 2002, 41, 15360–15368. [PubMed: 12484775]
- (39). Biesalski HK; Chichili GR; Frank J; von Lintig J; Nohr D Conversion of beta-carotene to retinal pigment. *Vitam. Horm.* 2007, 75, 117–130. [PubMed: 17368314]
- (40). Quadro L; Blaner WS; Salchow DJ; Vogel S; Piantedosi R; Gouras P; Freeman S; Cosma MP; Colantuoni V; Gottesman ME Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. *EMBO J.* 1999, 18, 4633–4644. [PubMed: 10469643]
- (41). Quadro L; Hamberger L; Colantuoni V; Gottesman ME; Blaner WS Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models. *Mol. Aspects Med.* 2003, 24, 421–430. [PubMed: 14585313]
- (42). Wolf G A case of human vitamin A deficiency caused by an inherited defect in retinol-binding protein without clinical symptoms except night blindness. *Nutr. Rev.* 1999, 57, 258–260. [PubMed: 10518414]
- (43). Seeliger MW; Biesalski HK; Wissinger B; Gollnick H; Gielen S; Frank J; Beck S; Zrenner E Phenotype in retinol deficiency due to a hereditary defect in retinol binding protein synthesis. *Invest. Ophthalmol. Visual Sci.* 1999, 40, 3–11. [PubMed: 9888420]
- (44). Chichili GR; Nohr D; Schaffer M; von Lintig J; Biesalski HK beta-Carotene conversion into vitamin A in human retinal pigment epithelial cells. *Invest. Ophthalmol. Visual Sci.* 2005, 46, 3562–3569. [PubMed: 16186334]
- (45). Thompson CL; Blaner WS; Van Gelder RN; Lai K; Quadro L; Colantuoni V; Gottesman ME; San car A Preservation of light signaling to the suprachiasmatic nucleus in vitamin A-deficient mice. *Proc. Natl. Acad. Sci. U.S.A.* 2001, 98, 11708–11713. [PubMed: 11562477]
- (46). Wolf G Retinol transport and metabolism in transthyretin-“knockout” mice. *Nutr. Rev.* 1995, 53, 98–99. [PubMed: 7624065]
- (47). Racz B; Varadi A; Kong J; Allikmets R; Pearson PG; Johnson G; Cioffi CL; Petrukhin K A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle. *J. Biol. Chem.* 2018, 293, 11574–11588. [PubMed: 29871924]
- (48). Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. *J. Clin. Oncol.* 2001, 19, 1664–1670. [PubMed: 11250995]

Figure 1.

All-*trans*-retinol or vitamin A (**1**), the retinoid RBP4 antagonist fenretinide (**2**), the nonretinoid piperidine-based RBP4 antagonist A1120 (**3**), and the rationally designed bicyclic analogues **4** and BPN-14136 (**5**).

Figure 2. *N*-Benzyl imidazole RBP4 antagonist **6** and the SAR strategy used to discover novel RBP4 antagonists containing 2- and 3-carboxamido-fused [5,6]-bicyclic heteroaromatic appendages.

A Core Scaffold Modifications Explored **B Carboxamido Fused [5,6]-Bicyclic Heterocyclic Isosteres of the *N*-Benzyl Imidazole of Lead 6 Explored**

Initial SAR exploration from lead 6:
3-carboxamido fused [5,6]-bicyclic
heteroaromatic appendages installed on cores A and B:

Follow-up SAR exploration:
2-carboxamido fused [5,6]-bicyclic
heteroaromatic appendages:

Figure 3.

Structure-based drug design strategy used to discover novel RBP4 antagonists containing 3- and 2-carboxamido-fused [5,6]-bicyclic heteroaromatic appendages starting from lead **6**. (A) The piperidine (**A**) and bicyclic octahydrocyclopenta[*c*]pyrrole (**B**) scaffold core systems used in the SAR campaign. (B) The initial 3-carboxy-amido and subsequent 2-carboxy-amido-fused [5,6]-bicyclic heteroaromatic bottom group motifs explored.

Figure 4.

(A) Binding conformation of anthranilic acid antagonist **3** and key H-bond interactions with RBP4, as depicted within 3FMZ. The image is in a stick model format. Carbon atoms are shown as gray for the ligand and white for the protein, oxygen atoms are red, nitrogen atoms are blue, chlorine atoms are green, and sulfur atoms are yellow. H bonds are indicated as blue dotted lines, and the residues undergoing H-bond interactions with **3** are labeled. The urea carbonyl of **3** engages in an H-bond interaction with backbone Leu37, whereas Arg121 forms a salt bridge and Glu98 H-bonds with the carboxylic acid. In addition, the anthranilic acid phenyl ring of **3** and Phe96 are engaged in an edge-to-face π - π binding interaction (not shown). Lastly, the distal 2-trifluoromethyl-substituted aromatic head group of **3** resides with the hydrophobic and vacuous β -ionone pocket and is positioned nearly orthogonal to the core piperidine ring. The image of PDB ID 3FMZ was obtained from the RCSB Protein Data Bank (PDB) (www.rcsb.org). (B) Bioactive conformation and binding interactions of *N*-benzyl imidazole antagonist **6** with RBP4, as depicted within 4PSQ. The amide carbonyl of **6** engages in an H-bond interaction with Leu37, and the imidazole N2 nitrogen H-bonds with the η NH₂ group of the Arg121 side chain. The distal 2-Cl-substituted aromatic head group of **3** also resides with the hydrophobic β -ionone pocket in a nearly orthogonal

position. The image is of PDB ID 4PSQ was obtained from the RCSB Protein Data Bank (PDB) (www.rcsb.org).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 5.

Comparison of the putative key binding interactions between anthranilic acid **3** and 3-carboxamido 1*H*-indazole **11** with RBP4. (A) Expanded view of the minimized bound conformation of **3**. H bonds with Gln98 and Tyr90 and a salt bridge with Arg121 are shown (blue lines). An additional H bond between the urea carbonyl oxygen of **11** with the backbone amide Leu37 is also present but out of view in this depiction. Hydrophobic molecular surfaces are shown as green and hydrophilic surfaces as purple. Contact preferences generated by Molecular Operating Environment (MOE) (Chemical Computing Group, Inc., Montreal, CA). (B) Expanded view of the 1*H*-indazole fragment of **11**. The 1*H*-indazole N2 nitrogen atom accepts an H bond from Arg121. An additional H bond between the amide carbonyl oxygen of **11** with the backbone amide Leu37 is also present but out of view in this depiction. Furthermore, a potential van der Waals interaction may be occurring between the 1*H*-indazole ring and the isobutyl group of Leu37. The carbon atoms of **11** are gray, and the carbon atoms of the resident RBP4 amino acid residues are green. Nitrogen atoms are shown as blue, and oxygen atoms are shown as red. Gray lines indicate van der Waals contacts.

Figure 6.

(A) Minimized bound conformation of RBP4 [1,2,4]triazolo[4,3-*a*]pyridine antagonist **48** within 3FMZ. (B) Minimized bound conformation of RBP4 fluorinated antagonist **59** within 3FMZ. H-bond interactions between the [1,2,4]triazolo[4,3-*a*]pyridine N2 nitrogen atom and Arg121 near the opening of the RBP4 binding cavity are highlighted. An H bond between the carbonyl oxygen of **48** and **59** with the backbone amide Leu37 is also present but out of view in this depiction. The aryl head groups of both compounds are shown residing within the hydrophobic β -ionone pocket located deep within the RBP4 binding cavity.

Figure 7.

(A) Minimized bound conformation of RBP4 azaindole antagonist **69** within 3FMZ. (B) Minimized bound conformation of RBP4 azaindole antagonist **70** within 3FMZ. The 6-position of the indole ring of **69** resulted in a 5-fold loss in RBP4 binding affinity and a 2-fold loss in HTRF potency compared with parent indole **68**. However, positioning a nitrogen at the 4-position to give **70** restored binding affinity while significantly improving HTRF potency relative to **68**. Our docking model suggests that the position of the 1*H*-pyrrolo[3,2-*b*]pyridine nitrogen of **70** brings it within closer proximity to Gln98 and a putative structural water in the binding site relative to the indole ring nitrogen of **68**, resulting in more stable H bonds. H-bond interactions are indicated with red and black lines.

Figure 8.

PK/PD properties of **59** in mice. (A, B) Plasma RBP4 levels in CD-1 mice following a single 5 mg/kg oral (A) and a single 2 mg/kg intravenous (B) administration of **59**. (C, D) Plasma compound levels following administration of a single oral 5 mg/kg dose (C) and a 2 mg/kg intravenous dose (D) of **59**. Data are represented as the mean $\pm$ SD. For each time point of blood collection, three mice were used in the study.

Figure 9.

Effect of oral administration of compound **59** on circulating levels of serum RBP4 in adi-hRBP4 mice. Serum levels of mouse (A) and human (B) RBP4 were measured at baseline (black circles) and at the end of the 29 day compound treatment (red squares) with species-specific rodent or human enzyme-linked immunosorbent assay tests, as described in the Supporting Information. Compared with baseline, statistically significant 90% reduction was seen for both human and mouse RBP4 at the study's end in the **59**-treated mice (two-way analysis of variance (ANOVA) with Holm-Šidák post-hoc test, **** $P < 0.0001$). A significant reduction in human and mouse RBP4 concentrations was detected in **59**-treated adi-hRBP4 mice in comparison with vehicle-treated knockout controls (two-way ANOVA with Holm-Šidák post-hoc test, $P < 0.0001$). Error bars show SD; graph bars show mean. Each data point on the graph represents a serum RBP4 concentration from an individual animal. The number of male adi-hRBP4 mice per treatment group were 8 for normal chow, 7 for HFD, and 8 for HFD with **59**.

Figure 10.

Analogue 59 partially prevents high-fat diet-induced obesity in adi-hRBP4 mice. (A) Weight gains for male adi-hRBP4 mice fed with normal chow ($n = 8$), HFD ($n = 7$), and HFD with **58** ($n = 8$). In comparison to the untreated HFD group, compound-treated HFD mice registered significantly decreased weight gain at four time points starting from day 19 (two-way repeated measures (RM) ANOVA with Holm-Šidák post-hoc test, * $P < 0.05$; ** $P < 0.01$). The body weight gain in chow-fed mice was lower than in the HFD group at all time points studied (two-way RM ANOVA with Holm-Šidák post-hoc test, *** $P < 0.001$; **** $P < 0.0001$). Values represent mean percent weight change from baseline. Error bars show SD. Body weights of individual animals from three treatment groups are shown in Table S1. (B) Daily food consumption normalized to body weight in male adi-hRBP4 mice fed with normal chow, HFD, and HFD with **59**. No difference in food consumption between the untreated HFD group and compound-treated HFD mice was detected (two-way RM ANOVA with Holm-Šidák post-hoc test). Values represent mean normalized daily chow consumption. Error bars show SD.

Figure 11.

Effect of analogue **59** orally administered at the 20 mg/kg dose on hepatic free fatty acid and triglyceride levels in obese adi-hRBP4 mice. Liver levels of FFA (A) and TG (B) in male adi-hRBP4 mice fed with normal chow ($n = 8$), HFD ($n = 7$), and HFD with **59** ($n = 8$). In comparison with the untreated HFD group, **59**-treated HFD mice have significantly decreased hepatic levels of FFA ($P = 0.0107$, one-way ANOVA with Holm–Šidák post-hoc test) and triglycerides ($P = 0.0104$, one-way ANOVA with Holm–Šidák post-hoc test). Graph bars show mean; error bars show SD; * $P < 0.05$; **** $P < 0.0001$. Each data point on the graph represents a FFA or TG concentration from an individual animal.

Figure 12.

Effect of analogue **59** on hepatic lipid disposition in adi-hRBP4 mice. (A) Representative liver cryosections stained with oil red O illustrating fatty liver states in chow-fed, HFD, and **59**-treated HFD adi-hRBP4 mice. The compound was orally administered at the 20 mg/kg dose. (B) Histological scoring of oil red O-stained liver cryosections from chow-fed, HFD, and **59**-treated HFD adi-hRBP4 mice. Hepatic steatosis was graded as 0 (0% hepatocytes have macrovesicular steatosis), 1 (<33% hepatocytes have macrovesicular steatosis), 2 (33–66% hepatocytes have macrovesicular steatosis), and 3 (>66% hepatocytes have macrovesicular steatosis). Data was analyzed using one-way ANOVA with Holm–Šidák post-hoc test. Graph bars show mean; error bars show SD; *** $P < 0.001$. Each data point on the graph represents a steatosis histology score from an individual animal. The number of

male adi-hRBP4 mice per treatment group were 8 for normal chow, 7 for HFD, and 8 for HFD with **59**.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 13.

Binding of fatty acids to RBP4. (A) Isotherms of palmitic acid, oleic acid, linoleic acid, and docosahexaenoic acid binding to human RBP4. ³H-retinol at 10 nM was used as a radioligand. (B) Overlays of minimized bound conformations of retinol (black, 5NU7), antagonist **48** (purple, 3FMZ), and palmitic acid, oleic acid, linoleic acid, and docosahexaenoic acid (orange). Phe36 is dark-green in the 3FMZ (within close proximity to the fatty acid carboxylic acid groups) and light green in the 5NU7 model (within close proximity to the alcohol group of **1**). Contacting residues are labeled and illustrated in stick format (MOE, Chemical Computing Group, Inc., Montreal, CA).

Scheme 1.

^aReagents and conditions: (a) (i) *n*-BuLi, tetrahydrofuran (THF), $-78^{\circ}C$, 40 min; (ii) 1-benzylpiperidin-4-one, THF, $-78^{\circ}C$; (b) $SOCl_2$, $0^{\circ}C$, 2 h; (c) (i) HCO_2NH_4 , 10% Pd/C, CH_3OH , reflux, 2 h; (ii) 4.0 M HCl solution in 1,4-dioxane, CH_3CN , room temperature (rt), 2 h; (d) substituted indazole-3-carboxylic acid, HBTU, Et_3N , dimethylformamide (DMF), rt, 16 h.

Scheme 2.

^aReagents and conditions: (a) iodoethane or 2-iodopropane, K_2CO_3 , DMF, rt, 4 h; (b) 3-iodooxetane, K_2CO_3 , DMF, 60 °C, 24 h.

Scheme 3.

^aReagents and conditions: (a) benzo[*d*]isoxazole-3-carboxylic acid, HBTU, Et₃N, DMF, rt, 16 h; (b) benzo[*c*]isoxazole-3-carboxylic acid, HBTU, Et₃N, DMF, rt, 16 h.

Scheme 4.

^aReagents and conditions: (a) (i) LiAlH_4 (1.0 M solution in THF), THF, 70 °C, 16 h; (ii) Boc_2O , CH_2Cl_2 , rt, 16 h; (b) (i) NaIO_4 , $\text{RuO}_2 \cdot \text{H}_2\text{O}$, CH_3CN , CCl_4 , H_2O , rt, 24 h; (c) Ac_2O , NaOAc , 120 °C, 3 h; (d) (i) LiHMDS (1.0 M solution in THF), THF, -78 °C, 30 min; (ii), $\text{PhN}(\text{SO}_2\text{CF}_3)_2$, THF, -78 °C to rt, 3 h; (e) (2-(trifluoromethyl)phenyl)boronic acid, $\text{Pd}(\text{PPh}_3)_4$, 2.0 M Na_2CO_3 , dimethoxyethane (DME), 80 °C, 6 h; (f) H_2 (40 psi), 10% Pd/C , CH_3OH , rt, 16 h; (g) 2.0 M HCl in Et_2O , CH_2Cl_2 , 0 °C to rt, 24 h.

Scheme 5.

^aReagents and conditions: (a) (i) substituted 2-hydrazinylpyridine, ethyl 2-oxoacetate, CH₃OH, 60 °C, 1 h; (ii) PhI(OAc)₂, CH₂Cl₂, rt, 1 h; (b) (i) LiOH·H₂O, THF, H₂O, rt, 20 min; (ii) 2.0 N aqueous HCl; (c) **10**, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (d) **31**, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h.

Scheme 6.

^aReagents and conditions: (a) **10**, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (b) **31**, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (c) Zn(CN)₂, Pd(PPh₃)₄, DMF, 130 °C (microwave irradiation), 30 min; (d) Fe(acac)₃, CH₃MgBr (1.4 M solution in THF/toluene), *N*-methyl-2-pyrrolidone (NMP), THF, rt, 1 h; (e) Zn(CN)₂, Pd(PPh₃)₄, DMF, 130 °C (microwave irradiation), 30 min; (f) (i) Mo(CO)₆, Pd(OAc)₂, xantphos, Cs₂CO₃, CH₃OH, 1,4-dioxane, 80 °C, 2 h; (iii) LiOH·H₂O, THF, H₂O, rt, 30 min; (iv) 2 N aqueous HCl; (g) *N,N*-dimethylurea, Pd(OAc)₂, xantphos, Cs₂CO₃, 1,4-dioxane, 100 °C, 6 h; (h) (i) benzyl thiol, *i*-Pr₂NEt, Pd(OAc)₂, xantphos, 1,4-dioxane, 110 °C, 16 h; (ii) *N*-chlorosuccinimide (NCS), HOAc, H₂O, rt, 3 h; (iii) *N*-methylamine, *i*-Pr₂NEt, CH₂Cl₂, rt, 2 h.

Scheme 7.

^aReagents and conditions: (a) (i) LiHMDS (1.0 M solution in THF), THF, -78°C , 1 h; (ii) $\text{PhN}(\text{SO}_2\text{CF}_3)_2$, THF, -78 to 0°C , 3 h; (b) (3-fluoro-2-(trifluoromethyl)phenyl)boronic acid, $\text{Pd}(\text{PPh}_3)_4$, 2.0 M aqueous K_2CO_3 , DME, 80°C , 6 h; (c) 10% Pd/C , H_2 (30 psi), EtOH, rt, 18 h; (d) 2.0 M HCl in Et₂O, CH₂Cl₂, rt, 18 h; (e) 44, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (f) $\text{Zn}(\text{CN})_2$, $\text{Pd}(\text{PPh}_3)_4$, DMF, 130°C (microwave irradiation), 30 min.

Scheme 8.

^aReagents and conditions: (a) (i) substituted aryl boronic acid, Pd(PPh₃)₄, 2.0 M aqueous K₂CO₃, DME, 80 °C, 6 h; (b) 2.0 M HCl in Et₂O, CH₂Cl₂, rt, 18 h; (c) (i) PtO₂, H₂ (1 atm), HOAc, EtOAc, rt, 72 h; (ii) 2.0 M HCl in Et₂O, CH₂Cl₂, rt, 18 h; (d) **44**, HBTU, Et₃N, *i*-Pr₂NEt, rt, 16 h; (e) Zn(CN)₂, Pd(PPh₃)₄, DMF, 130 °C (microwave irradiation), 30 min.

Scheme 9.

^aReagents and conditions: (a) 1*H*-benzo[*d*]imidazole-2-carboxylic acid, benzo[*d*]oxazole-2-carboxylic acid or benzo[*d*]thiazole-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (b) 10, 1*H*-indole-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (c) 1*H*-pyrrolo[2,3-*c*]pyridine-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (d) 1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (e) imidazo[1,2-*a*]pyridine-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (f) imidazo[1,2-*b*]pyridazine-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h.

Scheme 10.

^aReagents and conditions: (a) 6-chloroimidazo[1,2-*b*]pyridazine-2-carboxylic acid, HBTU, *i*-Pr₂NEt, DMF, rt, 16 h; (b) trimethylboroxine, Pd(dppf), K₂CO₃, 1,4-dioxane, H₂O, 110 °C, 5 h; (c) NaOCH₃, CH₃OH, 70 °C, 1 h; (d) potassium cyclopropyltrifluoroborate, Pd(OAc)₂, di-(1-admantyl)-*n*-butylphosphine, Cs₂CO₃, toluene, H₂O, 100 °C, 3 h; (e) pyrrolidine (neat), 100 °C, 3 h; (f) morpholine (neat), 120 °C, 2 h.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

RBP4 Binding Affinity, Functional RBP4–TTR Antagonism, Kinetic Aqueous Solubility, and Liver Microsomal Metabolic Stability Data for 3-Carboxamido Indazole and Benzisoxazole RBP4 Antagonists

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
3		15.0 ± 0.005	122 ± 0.035	ND	3.0	85	ND	4.85	2.97
11		6.42	46	7.4	7.5	0.0	0.6	4.21	3.98
12		3.71	56.1	3.6	0.7	0.0	0.2	3.87	4.56
13		4.71	49.0	3	68	0.2	8.7	4.41	3.91
14		7.53	67.1	<1.6	100	0.1	100	4.98	3.14

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
15		4.71	48.3	1.9	36	0.5	6.8	4.41	3.91
16		6.99	58.6	<1.6	100	0.8	51	4.98	3.17
17		44.6	843	ND	ND	ND	ND	4.34	3.01
18		5.47	82.5	2.5	78	0.2	34	4.98	3.28
19		9.54	242	2.1	1.3	0.3	1.2	4.55	3.47

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
20		128	ND	ND	ND	ND	ND	4.86	2.03
21		4.12	35.6	4.7	0.1	10	4.3	3.57	4.81
22		6.28	79.5	8.4	0.4	0.0	0.0	3.97	4.23
23		8.26	98.8	6.2	1.5	0.0	0.0	3.97	4.11

^aFor compounds tested more than twice, IC₅₀ is represented as the mean ± standard deviation (SD). Otherwise, IC₅₀ is shown as the mean of two independent experiments.

^bKinetic aqueous solubility measured in PBS, pH 7.4. Verapamil and tamoxifen were used as controls.

^cHLM = human liver microsomes.

^dRLM = rat liver microsomes.

^eMLM = mouse liver microsomes. Compound concentration was 10 μM, and incubation time with either human, rat, or mouse microsomes was 30 min. Testosterone was used as a positive control. cLog *P* derived from ChemDraw Professional (ChemOffice Professional, CambridgeSoft and PerkinElmer). LLE = lipophilic ligand efficiency: RBP4 SPA/IC₅₀ – cLog *P*. ND = not determined.

Table 2.

RBP4 Binding Affinity, Functional RBP4-TTR Antagonism, Kinetic Aqueous Solubility, and Liver Microsomal Metabolic Stability Data For [1,2,4]Triazolo[4,3-*a*]pyridine RBP4 Antagonists

Compound Number/ Scaffold Core	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
34/A		4.55	22.5	8	80	4.9	2.4	2.89	5.45
35/A		4.01	25.2	11	81	22	44	3.46	4.93

Compound Number/ Scaffold Core	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
36/A		3.70	12.8	25	74	31	32	3.17	5.26
37/A		3.97	20.6	2.5	77	31	2.5	3.70	4.70
38/A		3.75	28.3	1.9	85	92	98	3.64	4.78
39/B		4.1	67.5	9.3	53	1.6	44	3.21	5.17
40/B		4.5	49.3	<1.6	61	2.3	3	3.78	4.56
41/B		6.0	61.7	4.5	47	7.8	7.2	3.48	4.74
42/B		2.7	71.4	<1.6	57	39	8.2	4.01	4.55

Compound Number/ Scaffold Core	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
43/B		3.4	10.6	<1.6	76	69	61	3.95	4.51
48/A		5.14	60.9	44	99	82	100	2.20	6.08
49/A		3.9	16.6	28.6	100	57	27	3.25	5.15
51/B		6.0	90.3	<1.6	27	31	45	2.51	5.71
52/B		32.8	895	84	81	83	72	3.16	4.32
53/B		14.6	240.6	17	19	19	4.2	2.85	4.98
54/B		10.0	211.5	<1.6	25	61	40	2.80	5.20

^aFor compounds tested more than twice, IC₅₀ is represented as the mean ± standard deviation. Otherwise, IC₅₀ is shown as the mean of two independent experiments.

^bKinetic aqueous solubility measured in PBS, pH 7.4. Verapamil and tamoxifen were used as controls.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

c_{HLM} = human liver microsomes.

c_{RLM} = rat liver microsomes.

c_{MLM} = mouse liver microsomes. The compound concentration was 10 μ M and incubation time with either human, rat, or mouse microsomes was 30 min. Testosterone was used as a positive control. cLog

P is derived from ChemDraw Professional (ChemOffice Professional, CambridgeSoft and PerkinElmer). LLE = lipophilic ligand efficiency; RBP4 SPA pIC₅₀ – cLog P . ND = not determined.

Table 3.

RBP4 Binding Affinity, Functional RBP4-TTR Antagonism, Kinetic Aqueous Solubility, and Liver Microsomal Stability Data for [1,2,4]Triazolo[4,3-*a*]pyridine RBP4 Antagonists with Fluorinated Aryl Head Groups

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)			cLogP	LLE
					HLM ^c	RLM ^d	MLM ^e		
59		5.73	16.05	33	100	60	87	2.34	5.90
61		4.88	23.21	7.5	78	8.9	59	2.34	5.97
62		9.06	19.77	31	ND	ND	ND	2.34	5.70
64		5.84	92.02	28	ND	ND	ND	2.34	5.89

^aFor compounds tested more than twice, IC₅₀ is represented as the mean ± standard deviation. Otherwise, IC₅₀ is shown as the mean of two independent experiments.

^bKinetic aqueous solubility measured in PBS, pH 7.4. Verapamil and tamoxifen were used as controls.

^cHLM = human liver microsomes.

^dRLM = rat liver microsomes.

^eMLM = mouse liver microsomes. The compound concentration was 10 μM, and incubation time with either human, rat, or mouse microsomes was 30 min. Testosterone was used as a positive control. cLog P is derived from ChemDraw Professional (ChemOffice Professional, CambridgeSoft and PerkinElmer). ND = not determined.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

RBP4 Binding Affinity, Functional RBP4-TTR Antagonism, Kinetic Aqueous Solubility, and Liver Microsomal Stability Data for 2-Carboxamido RBP4 Antagonists of Diverse Fused [5,6]-Bicyclic Heteroaromatic Systems

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^d IC ₅₀ (nM)	Kinetic Solubility ^b (μ M)	Microsomal Stability (% remaining)		
					HLM ^c	RLM ^d	MLM ^e
65		6.82	343	ND	ND	ND	ND
66		8.5	157	2.9	0.4	0.0	0.0
67		9.61	472	ND	ND	ND	ND
68		15.9	1780	ND	ND	ND	ND
69		84.2	3720	ND	ND	ND	ND
70		29.8	141	<1.6	49	1.0	6.7
71		9.71	211	51	9.0	0.0	0.0

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^d IC ₅₀ (nM)	Kinetic Solubility ^b (μM)	Microsomal Stability (% remaining)		
					HLM ^c	RLM ^d	MLM ^e
72		4.98	27.9	83	3.7	0.5	0.3

^aFor compounds tested more than twice, IC₅₀ is represented as the mean ± standard deviation. Otherwise, IC₅₀ is shown as the mean of two independent experiments.

^bKinetic aqueous solubility is measured in PBS, pH 7.4. Verapamil and tamoxifen were used as controls.

^cHLM = human liver microsomes.

^dRLM = rat liver microsomes.

^eMLM = mouse liver microsomes. The compound concentration was 10 μM and the incubation time with either human, rat, or mouse microsomes was 30 min. Testosterone was used as a positive control. ND = not determined.

Table 5.

BBP4 Binding Affinity, Functional RBP4-TTR Antagonism, Kinetic Aqueous Solubility, and Liver Microsomal Stability Data for Imidazo[1,2-*b*]pyridazine-2-carboxamide Analogues

Compound Number	R	RBP4 SPA ^a IC ₅₀ (nM)	RBP4 HTRF ^a IC ₅₀ (nM)	Kinetic Solubility ^b (μ M)	Microsomal Stability (% remaining)		
					HLM ^c	RLM ^d	MLM ^e
74		2.66	32.6	72	67	12	0.2
75		6.36	36.8	47	99	47	1.0
76		3.6	103	14	73	51	0.4
77		10.8	134	5.6	45	2.1	4.9
78		6.74	112	47	65	53	44

^aFor compounds tested more than twice, IC₅₀ is represented as the mean $\pm$ standard deviation. Otherwise, IC₅₀ is shown as the mean of two independent experiments.

^bKinetic aqueous solubility measured in PBS, pH 7.4. Verapamil and tamoxifen were used as controls.

^cHLM = human liver microsomes.

^dRLM = rat liver microsomes.

^eMLM = mouse liver microsomes. The compound concentration was 10 μ M, and the incubation time with either human, rat, or mouse microsomes was 30 min. Testosterone was used as a positive control. ND = not determined.

Table 6.

In Vitro Metabolic Stability, CYP Inhibition, and %PPB Profiles for 48 and 59

no.	microsomal CL _{int} (μL/(min mg) ^a				CYP inhibition (μM IC ₅₀)				%PPB ^b			tPSA ^{c,d}	cLog P ^d
	H	R	D	cyno	2C9	2C19	2D6	3A4	H	R	M		
48	5.9	31	4.9	9.4	4.7	30	>100	50	96.9	97.9	95.1	72.06	2.20
59	5.9	29	7.7	8.6	11	22	>100	74	97.0	98.7	98.5	72.06	2.34

^a Intrinsic clearance (CL_{int}) in the presence of microsomes; H = human; R = rat; D = dog; cyno = cynomolgus monkey.^b %PPB = percent plasma protein binding. H = human; R = rat; M = mouse.^c tPSA = topological surface area.^d tPSA and cLog P derived from ChemDraw Professional (Chem Office Professional, CambridgeSoft and PerkinElmer).

In Vitro ADMET Profiles for 48 and 59 Continued

^d Strains of *Salmonella typhimurium* tested in the full Ames studies: TA97, TA98, TA102, TA100, TA1535, TA1537, and TA1538.

In Vivo PK Data for Analogues 48 and 59 Following IV and PO Administration in Rodent^a

Table 8.

no.	species	CL ^b (mL/h/kg)	C _{max} ^c (ng/mL)	T _{max} ^d (h)	T _{1/2} ^e (h)	V _{ss} ^f (mL/kg)	AUC _{last} ^g (h·ng/mL)	%F ^h
48	Mouse ⁱ	163.5	1590	2.00	4.7	1123	16402	53.7
	rat ^h	755 ± 49	410 ± 165	1.00 ± 0.0	6.0 ± 0.5	2203 ± 479	2815 ± 908	42.6 ± 13.7
59	Mouse ⁱ	350	517	4	6.2	2954	8721	61.6
	rat ^j	1134	175	1.5	10.53	4281	1771	42.0

^aDosing groups consisted of three drug naïve male CD-1 mice or adult male Sprague-Dawley rats. Data are represented as mean ± SD.

^bTotal body clearance.

^cMaximum observed concentration of the compound in plasma.

^dTime of the maximum observed concentration of the compound in plasma after oral administration.

^eApparent half-life of the terminal phase of elimination of the compound from plasma.

^fVolume of distribution at a steady state.

^gArea under the plasma concentration versus time curve from 0 to the last time point compound was quantifiable in plasma.

^hBioavailability; $F = \left(\text{AUC}_{\text{INFpo}} \times \text{dose}_{\text{iv}} \right) \div \left(\text{AUC}_{\text{INFiv}} \times \text{dose}_{\text{po}} \right)$.

ⁱIntravenous (IV) formulation = 3% dimethylacetate/45% poly(ethylene glycol)300/12% ethanol/40% sterile water; IV dosing volume = 2 mL/kg; orally (PO) formulation = 2% Tween 80 in 0.9% saline; PO dosing volume = 5 mL/kg. Dosing regimen for **48** in mouse and rat: 2.0 mg/kg IV, 5 mg/kg PO. Dosing regimen for **59** in mouse: 2.0 mg/kg IV, 5 mg/kg PO. Dosing regimen for **59** in rat: 1.0 mg/kg IV, 2.0 mg/kg IV, 5 mg/kg PO.